oxonic acid has been researched along with Hyperuricemia in 140 studies
Oxonic Acid: Antagonist of urate oxidase.
Hyperuricemia: Excessive URIC ACID or urate in blood as defined by its solubility in plasma at 37 degrees C; greater than 0.42mmol per liter (7.0mg/dL) in men or 0.36mmol per liter (6.0mg/dL) in women. This condition is caused by overproduction of uric acid or impaired renal clearance. Hyperuricemia can be acquired, drug-induced or genetically determined (LESCH-NYHAN SYNDROME). It is associated with HYPERTENSION and GOUT.
| Excerpt | Relevance | Reference |
|---|---|---|
| " It suppressed liver xanthine oxidase activity to decrease uric acid synthesis and modulated renal urate transporters to stimulate uric acid excretion, alleviating kidney damage caused by hyperuricemia." | 8.31 | Paeonia × suffruticosa Andrews leaf extract and its main component apigenin 7-O-glucoside ameliorate hyperuricemia by inhibiting xanthine oxidase activity and regulating renal urate transporters. ( An, J; Li, C; Li, Y; Lin, F; Ma, S; Wang, S; Xie, Y; Xu, L; Zhang, Y; Zhao, Y, 2023) |
| " In this study, the xanthine oxidase (XO) inhibition and uric acid-lowering effect of corni fructus extract (CFE) were evaluated in mice with potassium oxonate-induced hyperuricemia." | 8.12 | Protective effects of corni fructus extract in mice with potassium oxonate-induced hyperuricemia. ( Chen, C; Chen, FA; Chen, HC; Chiu, PY; Li, YL; Wang, CC, 2022) |
| "Rats with hyperuricemia induced by fructose and potassium oxonate were administered with DoMRE and vehicle control, respectively, to compare the effects of the drugs." | 8.12 | Effects of Macroporous Resin Extract of Dendrobium officinale Leaves in Rats with Hyperuricemia Induced by Fructose and Potassium Oxonate. ( Chen, SH; Dong, YJ; He, XL; Li, B; Li, LZ; Lv, GY; Wang, YZ; Xu, WF; Yu, QX; Zheng, X; Zhou, C; Zhu, LJ, 2022) |
| "Insufficient renal urate excretion and/or overproduction of uric acid (UA) are the dominant causes of hyperuricemia." | 8.02 | Baicalein alleviates hyperuricemia by promoting uric acid excretion and inhibiting xanthine oxidase. ( Cao, Y; Chen, Y; Jiang, Y; Li, L; Li, Y; Lin, C; Pang, J; Tian, Y; Wu, T; Yang, Y; Zhao, Z; Zhou, P, 2021) |
| "The study was designed to explore the effects of Withaferin A (WFA) on hyperuricemia-induced kidney injury and its action mechanism." | 8.02 | Withaferin A protects against hyperuricemia induced kidney injury and its possible mechanisms. ( Bai, Y; Li, P; Ru, J; Tang, L; Wang, J; Zhao, X, 2021) |
| "Hyperuricemia (HUA) is induced by abnormal purine metabolism and elevated serum uric acid (UA) concentrations, and it is often accompanied by inflammatory responses and intestinal disorders." | 8.02 | Chlorogenic acid supplementation ameliorates hyperuricemia, relieves renal inflammation, and modulates intestinal homeostasis. ( Hu, N; Lin, Y; Wang, J; Wang, S; Wang, X; Zhang, B; Zhao, X; Zhou, X, 2021) |
| " The effects of API on renal function, inflammation, fibrosis, and uric acid (UA) metabolism in mice with HN were evaluated." | 8.02 | Apigenin ameliorates hyperuricemic nephropathy by inhibiting URAT1 and GLUT9 and relieving renal fibrosis via the Wnt/β-catenin pathway. ( Cao, Y; Chen, Y; Huang, Q; Jiang, Y; Li, L; Li, Y; Luo, J; Pang, J; Wu, T; Zhang, L; Zhao, Z; Zhou, P, 2021) |
| " Male SD rats were assigned to control group or oxonic acid-induced hyperuricemia (HUA) group." | 7.96 | ABCG2 expression and uric acid metabolism of the intestine in hyperuricemia model rat. ( Asakawa, S; Hosoyamada, M; Kuribayashi-Okuma, E; Li, J; Morimoto, C; Murase, T; Nakamura, T; Nemoto, Y; Shibata, S; Tamura, Y; Uchida, S, 2020) |
| " The present study was undertaken to evaluate the therapeutic effects and the underlying mechanisms of polydatin on potassium oxonate-induced hyperuricemia in rats through metabonomic technology from a holistic view." | 7.96 | NMR-Based Metabonomic Study Reveals Intervention Effects of Polydatin on Potassium Oxonate-Induced Hyperuricemia in Rats. ( Gong, M; Han, B; Li, Z; Qiu, Y; Zou, Z, 2020) |
| "Potassium oxonate (PO) was used to establish a mouse model of hyperuricemia." | 7.91 | Modified Chuanhu anti-gout mixture, a traditional Chinese medicine, protects against potassium oxonate-induced hyperuricemia and renal dysfunction in mice. ( Che, K; Fei, H; Hou, X; Wang, J; Wang, Y; You, W; Zou, Y, 2019) |
| " The RSGE treatment dose-dependently reduced PO- and MSU-induced paw edema, serum TNF-α, IL-1β, IL-6, IL-12, uric acid, and BUN, while significantly elevated serum IL-10, urinary uric acid and creatinine levels as compared with the respective values in the hyperuricemic and gouty mice group (vehicle group)." | 7.91 | Protective effects of Rhizoma smilacis glabrae extracts on potassium oxonate- and monosodium urate-induced hyperuricemia and gout in mice. ( Chang, Y; Liang, C; Liang, G; Nie, Y; Xiao, D; Zeng, S; Zhan, S; Zheng, Q; Zheng, X, 2019) |
| " Curcumin (CUR), a natural polyphenol component extracted from the rhizome of Curcuma longa, has been reported to treat various symptoms such inflammation disease, seems to be efficacious in hyperuricemia." | 7.91 | Curcumin attenuates potassium oxonate-induced hyperuricemia and kidney inflammation in mice. ( Chen, Y; Duan, S; Hou, S; Li, C; Liang, J; Yuan, X, 2019) |
| "After oral administration of Dioscin in potassium oxonate (PO) induced hyperuricemia rats and adenine-PO induced hyperuricemia mice models, serum uric acid and creatinine levels, clearance of uric acid and creatinine, fractional excretion of uric acid, and renal pathological lesions were determined were used to evaluate the antihyperuricemic effects." | 7.88 | Effect and mechanism of dioscin from Dioscorea spongiosa on uric acid excretion in animal model of hyperuricemia. ( Chen, Q; Jin, L; Li, J; Liu, J; Wang, T; Wang, W; Yu, H; Zhang, Y, 2018) |
| "Hyperuricemia was induced by potassium oxonate in male rats." | 7.88 | Hypouricemic and Nephroprotective Effects of an Active Fraction from Polyrhachis Vicina Roger On Potassium Oxonate-Induced Hyperuricemia in Rats. ( Chen, N; Chu, S; He, F; Li, D; Liao, L; Lu, W; Nong, Z; Su, H; Su, Q; Wang, L; Wei, B; Wei, G; Ya, Q; Zeng, X; Zhao, J, 2018) |
| "Potassium oxonate, a selectively competitive uricase inhibitor, produced hyperuricemia (HUA) in rodents in a previous study." | 7.85 | Potassium oxonate induces acute hyperuricemia in the tree shrew (tupaia belangeri chinensis). ( Li, ZL; Ma, KL; Tang, DH; Wang, CY; Ye, YS; Zheng, H, 2017) |
| "Although radon therapy is indicated for hyperuricemia, the underlying mechanisms of action have not yet been elucidated in detail." | 7.83 | Difference in the action mechanism of radon inhalation and radon hot spring water drinking in suppression of hyperuricemia in mice. ( Etani, R; Ishimori, Y; Kanzaki, N; Kataoka, T; Mitsunobu, F; Sakoda, A; Tanaka, H; Yamaoka, K, 2016) |
| " The effects and possible molecular mechanisms of astilbin on potassium oxonate-induced hyperuricemia mice were investigated in this study." | 7.83 | Astilbin improves potassium oxonate-induced hyperuricemia and kidney injury through regulating oxidative stress and inflammation response in mice. ( Chen, J; Wang, M; Zhang, N; Zhao, J, 2016) |
| " Allopurinol is a commonly used medication to treat hyperuricemia and its complications." | 7.81 | Pallidifloside D from Smilax riparia enhanced allopurinol effects in hyperuricemia mice. ( Anderson, S; He, Y; Hou, PY; Mi, C; Wang, SQ; Wu, XH; Yu, F; Zhang, J; Zhang, YW, 2015) |
| "We tested whether melamine nephrotoxicity was exacerbated by urate (a typical component of renal stones in humans) in rats with hyperuricemiainduced by the uricase inhibitor, potassium oxonate (Oxo)." | 7.81 | Melamine Nephrotoxicity is Mediated by Hyperuricemia. ( Li, HT; Liu, JM; Trachtman, H; Trasande, L; Wang, LL; Wang, PX; Zhang, L, 2015) |
| "The aim of the present study was to investigate the effects of rutin on potassium oxonate-induced hyperuricemia and renal dysfunction in mice." | 7.79 | Beneficial effect of rutin on oxonate-induced hyperuricemia and renal dysfunction in mice. ( Chen, YS; Hu, QH; Kong, LD; Zhang, X; Zhu, Q, 2013) |
| "Experiments were performed in freshly harvested aortas from untreated animals and rats fed with oxonic acid (hyperuricemia), and compared to hyperuricemic rats treated with either allopurinol, benzbromarone or arginine." | 7.77 | Hyperuricemia attenuates aortic nitric oxide generation, through inhibition of arginine transport, in rats. ( Chernichovski, T; Engel, A; Grupper, A; Hillel, O; Schwartz, D; Schwartz, IF, 2011) |
| "As oxonic acid diet increased plasma renin activity, plasma aldosterone, and urine K to Na ratio, these changes may play a significant role in the harmful cardiovascular actions of hyperuricemia." | 7.74 | Oxonic acid-induced hyperuricemia elevates plasma aldosterone in experimental renal insufficiency. ( Eräranta, A; Kööbi, P; Kurra, V; Lakkisto, P; Mustonen, JT; Niemelä, OJ; Pörsti, IH; Tahvanainen, AM; Tikkanen, I; Vehmas, TI, 2008) |
| "The effect of febuxostat (Fx), a non-purine and selective xanthine oxidase inhibitor, on glomerular microcirculatory changes in 5/6 nephrectomy (5/6 Nx) Wistar rats with and without oxonic acid (OA)-induced hyperuricemia was evaluated." | 7.74 | Effect of febuxostat on the progression of renal disease in 5/6 nephrectomy rats with and without hyperuricemia. ( Avila-Casado, C; Franco, M; Johnson, RJ; Sánchez-Lozada, LG; Soto, V; Tapia, E; Wessale, JL; Zhao, L, 2008) |
| "Hyperuricemia is the primary cause of gouty arthritis and other metabolic disorders." | 5.62 | Eggshell Membrane Ameliorates Hyperuricemia by Increasing Urate Excretion in Potassium Oxonate-Injected Rats. ( Kim, DS; Sung, YY, 2021) |
| " However, BBR exhibits low bioavailability due to its extensive metabolism and limited absorption." | 5.62 | Berberrubine attenuates potassium oxonate- and hypoxanthine-induced hyperuricemia by regulating urate transporters and JAK2/STAT3 signaling pathway. ( Chen, J; Huang, Z; Jiang, L; Li, Y; Lin, G; Lin, Z; Liu, Y; Mai, L; Su, Z; Xie, J; Xu, L; Yu, Q, 2021) |
| "Inflammation is an important pathological feature of hyperuricemia, which in turn aggravates hyperuricemia." | 5.62 | Astaxanthin attenuated hyperuricemia and kidney inflammation by inhibiting uric acid synthesis and the NF-κ B/NLRP3 signaling pathways in potassium oxonate and hypoxanthine-induced hyperuricemia mice. ( Chen, Y; Liu, T; Yang, Z; Yuan, F; Zhang, L; Zhang, S; Zhou, X; Zhuang, J, 2021) |
| "Although hyperuricemia has been shown to be associated with the progression of cardiovascular disorder and chronic kidney disease (CKD), there is conflicting evidence as to whether xanthine oxidase (XO) inhibitors confer organ protection besides lowering serum urate levels." | 5.56 | Cardio-renal protective effect of the xanthine oxidase inhibitor febuxostat in the 5/6 nephrectomy model with hyperuricemia. ( Hayama, Y; Kuribayashi-Okuma, E; Morimoto, C; Omizo, H; Shibata, S; Tamura, Y; Uchida, S; Ueno, M, 2020) |
| "Hyperuricemia is an important risk factor of chronic kidney disease, metabolic syndrome and cardiovascular disease." | 5.56 | The Time-Feature of Uric Acid Excretion in Hyperuricemia Mice Induced by Potassium Oxonate and Adenine. ( Bao, R; Chen, Q; Liu, L; Liu, M; Wang, D; Wang, T; Wen, S; Yu, H; Zhang, Y, 2020) |
| "Gout that caused by hyperuricemia affects human health seriously and more efficient drugs are urgently required clinically." | 5.51 | New Rice-Derived Short Peptide Potently Alleviated Hyperuricemia Induced by Potassium Oxonate in Rats. ( Bian, W; Hu, Y; Liu, N; Meng, B; Sun, J; Wang, S; Wang, Y; Xiong, Z; Yang, M; Yang, X; Yin, S; Zeng, L, 2019) |
| "Hyperuricemia is highly prevalent and especially common in subjects with metabolic, cardiovascular and renal diseases." | 5.48 | Probiotic supplements prevented oxonic acid-induced hyperuricemia and renal damage. ( Blas-Marron, MG; Frank, DN; García-Arroyo, FE; Gonzaga, G; Ir, D; Irvin, A; Johnson, RJ; Muñoz-Jiménez, I; Ranganathan, N; Ranganathan, P; Robertson, CE; Sánchez-Lozada, LG; Silverio, O; Soto, V; Tapia, E; Vyas, U, 2018) |
| "Hyperuricemia is an independent risk factor for chronic kidney disease and cardiovascular disease." | 5.42 | Chinese Herbal Formulas Si-Wu-Tang and Er-Miao-San Synergistically Ameliorated Hyperuricemia and Renal Impairment in Rats Induced by Adenine and Potassium Oxonate. ( Gui, D; Guo, Y; Jiang, Q; Wang, N, 2015) |
| "Hyperuricemia is a biochemical hallmark of gout, renal urate lithiasis, and inherited purine disorders, and may be a result of enormous ATP breakdown or purine release as a result of cardiovascular disease, hypertension, kidney disease, eclampsia, obesity, metabolic syndrome, psoriasis, tumor lysis syndrome, or intense physical training." | 5.40 | Effect of commercial or depurinized milk on rat liver growth-regulatory kinases, nuclear factor-kappa B, and endonuclease in experimental hyperuricemia: comparison with allopurinol therapy. ( Andjelkovic, T; Chiesa, LM; Cvetkovic, T; Jevtovic-Stoimenov, T; Kocic, G; Kocic, H; Nikolic, G; Nikolic, R; Panseri, S; Pavlovic, R; Sokolovic, D; Stojanovic, S; Veljkovic, A, 2014) |
| "Hyperuricemia is related to a variety of pathologies, including chronic kidney disease (CKD)." | 5.39 | Hyperuricemia influences tryptophan metabolism via inhibition of multidrug resistance protein 4 (MRP4) and breast cancer resistance protein (BCRP). ( Dankers, AC; Dijkman, HB; Hoenderop, JG; Masereeuw, R; Mutsaers, HA; Russel, FG; Sweep, FC; van den Heuvel, LP, 2013) |
| " We therefore studied the effect of acute and chronic administration of l-arginine (a substrate for endothelial nitric oxide synthase) on the renal hemodynamic and vascular structural alterations induced by HU." | 5.34 | Effects of acute and chronic L-arginine treatment in experimental hyperuricemia. ( Avila-Casado, C; Franco, M; Herrera-Acosta, J; Johnson, RJ; López-Molina, R; Nakagawa, T; Nepomuceno, T; Sánchez-Lozada, LG; Soto, V; Tapia, E, 2007) |
| "Uric acid has promoted renal fibrosis and inflammation in experimental studies, but some studies have shown nephroprotective effects due to alleviated oxidative stress." | 4.31 | Moderate hyperuricaemia ameliorated kidney damage in a low-renin model of experimental renal insufficiency. ( Eräranta, A; Honkanen, T; Kurra, V; Lakkisto, P; Mustonen, J; Myllymäki, J; Paavonen, T; Pörsti, I; Riutta, A; Tikkanen, I, 2023) |
| " Hyperuricemia mice are induced via daily oral gavage of potassium oxonate and hypoxanthine." | 4.31 | Anti-Hyperuricemic, Nephroprotective, and Gut Microbiota Regulative Effects of Separated Hydrolysate of α-Lactalbumin on Potassium Oxonate- and Hypoxanthine-Induced Hyperuricemic Mice. ( Du, L; Shen, Y; Su, E; Wei, D; Xie, D; Xie, J, 2023) |
| " It suppressed liver xanthine oxidase activity to decrease uric acid synthesis and modulated renal urate transporters to stimulate uric acid excretion, alleviating kidney damage caused by hyperuricemia." | 4.31 | Paeonia × suffruticosa Andrews leaf extract and its main component apigenin 7-O-glucoside ameliorate hyperuricemia by inhibiting xanthine oxidase activity and regulating renal urate transporters. ( An, J; Li, C; Li, Y; Lin, F; Ma, S; Wang, S; Xie, Y; Xu, L; Zhang, Y; Zhao, Y, 2023) |
| "The anti-hyperuricemic bioactivity of the non-alkaloids fraction and compounds were evaluated with potassium oxonate (PO) induced hyperuricemia mice model in vivo, and monosodium urate (MSU) induced human renal tubular epithelial cells (HK-2) was selected to test in vitro, respectively, with benzobromarone as the positive control." | 4.12 | Anti-hyperuricemic bioactivity of Alstonia scholaris and its bioactive triterpenoids in vivo and in vitro. ( Hu, BY; Luo, XD; Ma, DY; Xiang, ML; Zhao, LX; Zhao, YL, 2022) |
| "Hyperuricemia is characterized with high serum uric acids (SUAs) and directly causes suffering gout." | 4.12 | Caffeic acid phenethyl ester alleviated hypouricemia in hyperuricemic mice through inhibiting XOD and up-regulating OAT3. ( Cai, M; Chen, S; Gao, X; Hu, H; Huang, L; Li, X; Liang, D; Liu, Y; Wu, Q; Xiao, C; Xie, Y; Yong, T, 2022) |
| " In this study, the xanthine oxidase (XO) inhibition and uric acid-lowering effect of corni fructus extract (CFE) were evaluated in mice with potassium oxonate-induced hyperuricemia." | 4.12 | Protective effects of corni fructus extract in mice with potassium oxonate-induced hyperuricemia. ( Chen, C; Chen, FA; Chen, HC; Chiu, PY; Li, YL; Wang, CC, 2022) |
| "Rats with hyperuricemia induced by fructose and potassium oxonate were administered with DoMRE and vehicle control, respectively, to compare the effects of the drugs." | 4.12 | Effects of Macroporous Resin Extract of Dendrobium officinale Leaves in Rats with Hyperuricemia Induced by Fructose and Potassium Oxonate. ( Chen, SH; Dong, YJ; He, XL; Li, B; Li, LZ; Lv, GY; Wang, YZ; Xu, WF; Yu, QX; Zheng, X; Zhou, C; Zhu, LJ, 2022) |
| " Both WP and EP extracts showed pronounced antihyperuricemia activities, with a remarkable decline in serum uric acid and a marked increase in urine uric acid in hyperuricemic mice." | 4.02 | Antihyperuricemia and antigouty arthritis effects of Persicaria capitata herba in mice. ( Chen, TX; Dong, L; Fu, Y; Guan, HY; He, X; Liao, SG; Tang, KF; Xu, GB; Yang, XS; Yang, YX; Zhang, CL; Zhang, JJ; Zhu, QF, 2021) |
| "Insufficient renal urate excretion and/or overproduction of uric acid (UA) are the dominant causes of hyperuricemia." | 4.02 | Baicalein alleviates hyperuricemia by promoting uric acid excretion and inhibiting xanthine oxidase. ( Cao, Y; Chen, Y; Jiang, Y; Li, L; Li, Y; Lin, C; Pang, J; Tian, Y; Wu, T; Yang, Y; Zhao, Z; Zhou, P, 2021) |
| "Hyperuricemia is defined by the European Rheumatology Society as a uric acid level greater than 6 mg/dl (60 mg/l or 360 μmol/l)." | 4.02 | Creation of an adequate animal model of hyperuricemia (acute and chronic hyperuricemia); study of its reversibility and its maintenance. ( Affes, H; Charfi, S; Dhouibi, R; Hammami, S; Jamoussi, K; Ksouda, K; Marekchi, R; Moalla, D; Sahnoun, Z; Salem, MB; Zeghal, KM, 2021) |
| "The study was designed to explore the effects of Withaferin A (WFA) on hyperuricemia-induced kidney injury and its action mechanism." | 4.02 | Withaferin A protects against hyperuricemia induced kidney injury and its possible mechanisms. ( Bai, Y; Li, P; Ru, J; Tang, L; Wang, J; Zhao, X, 2021) |
| "Hyperuricemia (HUA) is induced by abnormal purine metabolism and elevated serum uric acid (UA) concentrations, and it is often accompanied by inflammatory responses and intestinal disorders." | 4.02 | Chlorogenic acid supplementation ameliorates hyperuricemia, relieves renal inflammation, and modulates intestinal homeostasis. ( Hu, N; Lin, Y; Wang, J; Wang, S; Wang, X; Zhang, B; Zhao, X; Zhou, X, 2021) |
| " The effects of API on renal function, inflammation, fibrosis, and uric acid (UA) metabolism in mice with HN were evaluated." | 4.02 | Apigenin ameliorates hyperuricemic nephropathy by inhibiting URAT1 and GLUT9 and relieving renal fibrosis via the Wnt/β-catenin pathway. ( Cao, Y; Chen, Y; Huang, Q; Jiang, Y; Li, L; Li, Y; Luo, J; Pang, J; Wu, T; Zhang, L; Zhao, Z; Zhou, P, 2021) |
| "Hyperuricemia is caused by hepatic overproduction of uric acid and/or underexcretion of urate from the kidneys and small intestine." | 3.96 | Comprehensive analysis of mechanism underlying hypouricemic effect of glucosyl hesperidin. ( Harada-Shiba, M; Hirata, H; Ogura, M; Ota-Kontani, A; Tsuchiya, Y, 2020) |
| " A potassium oxonate (PO) induced hyperuricemic mouse model was used to evaluate antihyperuricemia and nephroprotective effects of O." | 3.96 | Antihyperuricemic and nephroprotective effects of extracts from Orthosiphon stamineus in hyperuricemic mice. ( Liang, ML; Su, WK; Sun, Y; Wang, HT; Xu, WH; Xue, ZC, 2020) |
| " Male SD rats were assigned to control group or oxonic acid-induced hyperuricemia (HUA) group." | 3.96 | ABCG2 expression and uric acid metabolism of the intestine in hyperuricemia model rat. ( Asakawa, S; Hosoyamada, M; Kuribayashi-Okuma, E; Li, J; Morimoto, C; Murase, T; Nakamura, T; Nemoto, Y; Shibata, S; Tamura, Y; Uchida, S, 2020) |
| " The present study was undertaken to evaluate the therapeutic effects and the underlying mechanisms of polydatin on potassium oxonate-induced hyperuricemia in rats through metabonomic technology from a holistic view." | 3.96 | NMR-Based Metabonomic Study Reveals Intervention Effects of Polydatin on Potassium Oxonate-Induced Hyperuricemia in Rats. ( Gong, M; Han, B; Li, Z; Qiu, Y; Zou, Z, 2020) |
| "Scopoletin (Sco) has great potential for hyperuricemia therapy." | 3.96 | Antihyperuricemic efficacy of Scopoletin-loaded Soluplus micelles in yeast extract/potassium oxonate-induced hyperuricemic mice. ( Ma, Y; Mao, J; Yang, Z; Zeng, Y; Zheng, Y, 2020) |
| "5% potassium oxonate (an uricase inhibitor) to induce hyperuricemia." | 3.91 | Feeding-produced subchronic high plasma levels of uric acid improve behavioral dysfunction in 6-hydroxydopamine-induced mouse model of Parkinson's disease. ( Dohgu, S; Fukae, J; Kataoka, Y; Koga, M; Matsumoto, J; Nakashima, A; Takata, F; Tsuboi, Y; Yamauchi, A, 2019) |
| "Metformin is always used as the baseline antidiabetic therapy for patients with type 2 diabetes mellitus (T2DM) and hyperuricemia." | 3.91 | Effect of high uric acid on the disposition of metformin: in vivo and in vitro studies. ( Ma, Y; Rao, Z; Sun, X; Wu, X; Xi, D; Zhang, G, 2019) |
| "With co-treatment of potassium oxonate (PO) and xanthine sodium salt (XSS), a zebrafish larva model of acute hyperuricemia has been constructed for the first time." | 3.91 | A zebrafish (danio rerio) model for high-throughput screening food and drugs with uric acid-lowering activity. ( Li, Q; Wang, F; Xing, C; Zhang, Y, 2019) |
| "Potassium oxonate (PO) was used to establish a mouse model of hyperuricemia." | 3.91 | Modified Chuanhu anti-gout mixture, a traditional Chinese medicine, protects against potassium oxonate-induced hyperuricemia and renal dysfunction in mice. ( Che, K; Fei, H; Hou, X; Wang, J; Wang, Y; You, W; Zou, Y, 2019) |
| " The RSGE treatment dose-dependently reduced PO- and MSU-induced paw edema, serum TNF-α, IL-1β, IL-6, IL-12, uric acid, and BUN, while significantly elevated serum IL-10, urinary uric acid and creatinine levels as compared with the respective values in the hyperuricemic and gouty mice group (vehicle group)." | 3.91 | Protective effects of Rhizoma smilacis glabrae extracts on potassium oxonate- and monosodium urate-induced hyperuricemia and gout in mice. ( Chang, Y; Liang, C; Liang, G; Nie, Y; Xiao, D; Zeng, S; Zhan, S; Zheng, Q; Zheng, X, 2019) |
| " Curcumin (CUR), a natural polyphenol component extracted from the rhizome of Curcuma longa, has been reported to treat various symptoms such inflammation disease, seems to be efficacious in hyperuricemia." | 3.91 | Curcumin attenuates potassium oxonate-induced hyperuricemia and kidney inflammation in mice. ( Chen, Y; Duan, S; Hou, S; Li, C; Liang, J; Yuan, X, 2019) |
| "After oral administration of Dioscin in potassium oxonate (PO) induced hyperuricemia rats and adenine-PO induced hyperuricemia mice models, serum uric acid and creatinine levels, clearance of uric acid and creatinine, fractional excretion of uric acid, and renal pathological lesions were determined were used to evaluate the antihyperuricemic effects." | 3.88 | Effect and mechanism of dioscin from Dioscorea spongiosa on uric acid excretion in animal model of hyperuricemia. ( Chen, Q; Jin, L; Li, J; Liu, J; Wang, T; Wang, W; Yu, H; Zhang, Y, 2018) |
| "Hyperuricemia was induced by potassium oxonate in male rats." | 3.88 | Hypouricemic and Nephroprotective Effects of an Active Fraction from Polyrhachis Vicina Roger On Potassium Oxonate-Induced Hyperuricemia in Rats. ( Chen, N; Chu, S; He, F; Li, D; Liao, L; Lu, W; Nong, Z; Su, H; Su, Q; Wang, L; Wei, B; Wei, G; Ya, Q; Zeng, X; Zhao, J, 2018) |
| " affine extract was evaluated in an experimental model with potassium oxonate (PO) induced hyperuricemia in mice which was used to evaluate anti-hyperuricemia activity and xanthine oxidase (XO) inhibition." | 3.85 | Effects of Gnaphalium affine D. Don on hyperuricemia and acute gouty arthritis. ( Cheng, L; Hu, YJ; Li, LN; Liang, WQ; Liu, PG; Pu, JB; Xu, P; Yang, QQ; Zhang, HJ; Zhang, YQ; Zhou, J, 2017) |
| "Potassium oxonate, a selectively competitive uricase inhibitor, produced hyperuricemia (HUA) in rodents in a previous study." | 3.85 | Potassium oxonate induces acute hyperuricemia in the tree shrew (tupaia belangeri chinensis). ( Li, ZL; Ma, KL; Tang, DH; Wang, CY; Ye, YS; Zheng, H, 2017) |
| "Although radon therapy is indicated for hyperuricemia, the underlying mechanisms of action have not yet been elucidated in detail." | 3.83 | Difference in the action mechanism of radon inhalation and radon hot spring water drinking in suppression of hyperuricemia in mice. ( Etani, R; Ishimori, Y; Kanzaki, N; Kataoka, T; Mitsunobu, F; Sakoda, A; Tanaka, H; Yamaoka, K, 2016) |
| " The effects and possible molecular mechanisms of astilbin on potassium oxonate-induced hyperuricemia mice were investigated in this study." | 3.83 | Astilbin improves potassium oxonate-induced hyperuricemia and kidney injury through regulating oxidative stress and inflammation response in mice. ( Chen, J; Wang, M; Zhang, N; Zhao, J, 2016) |
| "Uric acid is a metabolite obtained from purine by xanthine oxidase activity (XO) and high levels of serum uric acid leads to hyperuricemia and gout." | 3.83 | Hypouricemic effects of Mesona procumbens Hemsl. through modulating xanthine oxidase activity in vitro and in vivo. ( Hsu, CL; Jhang, JJ; Liao, JW; Lin, JH; Lu, CC; Ong, JW; Yen, GC, 2016) |
| " Allopurinol is a commonly used medication to treat hyperuricemia and its complications." | 3.81 | Pallidifloside D from Smilax riparia enhanced allopurinol effects in hyperuricemia mice. ( Anderson, S; He, Y; Hou, PY; Mi, C; Wang, SQ; Wu, XH; Yu, F; Zhang, J; Zhang, YW, 2015) |
| "This study evaluated the effects of crude drugs obtained from the silkworm in mice with oxonic acid-induced hyperuricemia using xanthine oxidase inhibitory activity and plasma uric acid levels." | 3.81 | [The Xanthine Oxidase Inhibitory Activity and Hypouricemic Effects of Crude Drugs Obtained from the Silkworm in Mice]. ( Minakuchi, N; Miyata, Y; Murakami, A; Sakazaki, F; Tanaka, R, 2015) |
| " oldhamii leaf extracts was investigated using potassium oxonate (PO)-induced acute hyperuricemia." | 3.81 | Antioxidative phytochemicals from Rhododendron oldhamii Maxim. leaf extracts reduce serum uric acid levels in potassium oxonate-induced hyperuricemic mice. ( Chiu, CC; Chuang, HL; Ho, ST; Huang, CC; Lin, CY; Lin, LC; Liu, YL; Tung, YT; Wu, JH, 2015) |
| "We tested whether melamine nephrotoxicity was exacerbated by urate (a typical component of renal stones in humans) in rats with hyperuricemiainduced by the uricase inhibitor, potassium oxonate (Oxo)." | 3.81 | Melamine Nephrotoxicity is Mediated by Hyperuricemia. ( Li, HT; Liu, JM; Trachtman, H; Trasande, L; Wang, LL; Wang, PX; Zhang, L, 2015) |
| " riparia in reducing serum uric acid levels in a potassium oxonate-induced hyperuricemia mouse model." | 3.80 | Smilax riparia reduces hyperuricemia in mice as a potential treatment of gout. ( Anderson, S; Wu, XH; Yu, CH; Zhang, CF; Zhang, YW, 2014) |
| "The hypouricemic actions of exopolysaccharide produced by Cordyceps militaris (EPCM) in potassium oxonate-induced hyperuricemia in mice were examined." | 3.80 | Hypouricemic actions of exopolysaccharide produced by Cordyceps militaris in potassium oxonate-induced hyperuricemic mice. ( Gao, J; Ma, L; Yuan, Y; Zhang, S, 2014) |
| "These results suggest that pallidifloside D possesses a potent uricosuric effect in hyperuricemic mice through decreasing renal mURAT1 and GLUT9, which contribute to the enhancement of uric acid excretion and attenuate hyperuricemia-induced renal dysfunction." | 3.80 | Pallidifloside D, a saponin glycoside constituent from Smilax riparia, resist to hyperuricemia based on URAT1 and GLUT9 in hyperuricemic mice. ( Ruan, JL; Wang, SQ; Wu, XH; Zhang, J; Zhang, YW, 2014) |
| " d-1 ) to prepare the hyperuricemia model, and divided into normal, model, Allopurinol, LE high dosage, middle dosage and low dose (200, 100, 50 mg ." | 3.80 | [Regulatory effect of leonurus extracts on hyperuricemia in rats]. ( An, YT; Li, J; Wang, T; Wu, ZZ; Yan, M, 2014) |
| "The aim of the present study was to investigate the effects of rutin on potassium oxonate-induced hyperuricemia and renal dysfunction in mice." | 3.79 | Beneficial effect of rutin on oxonate-induced hyperuricemia and renal dysfunction in mice. ( Chen, YS; Hu, QH; Kong, LD; Zhang, X; Zhu, Q, 2013) |
| "Treatment with Jianpihuashi Decoction for 30 days, the serum uric acid level of rats with hyperuricemia were significantly decreased (P < 0." | 3.79 | [Effect of jianpihuashi decoction on rats with hyperuricemia]. ( Chen, JW; Guo, J; Jiang, JM; Li, C; Xue, ZY; Zhou, LY; Zhou, Y, 2013) |
| " trichocarpha, its ethyl acetate fraction and its main bioactive compounds could be useful to treat gouty arthritis by countering hyperuricemia and inflammation." | 3.78 | Pharmacological basis for use of Lychnophora trichocarpha in gouty arthritis: anti-hyperuricemic and anti-inflammatory effects of its extract, fraction and constituents. ( de Paula, CA; de Souza Filho, JD; de Souza, MR; Grabe-Guimarães, A; Pereira de Resende, ML; Saúde-Guimarães, DA, 2012) |
| "The uricosuric and nephroprotective actions of resveratrol and its analogues were mediated by regulating renal organic ion transporters in hyperuricemic mice, supporting their beneficial effects for the prevention of hyperuricemia." | 3.78 | Antihyperuricemic and nephroprotective effects of resveratrol and its analogues in hyperuricemic mice. ( Hong, Y; Kong, LD; Li, Z; Liu, L; Liu, YL; Shi, YW; Wang, CP; Wang, X, 2012) |
| "These findings demonstrate that mangiferin has the potential to be developed as a new therapeutic agent for the treatment of hyperuricemia and gout." | 3.78 | Reducing effect of mangiferin on serum uric acid levels in mice. ( Gao, L; Li, L; Lin, H; Liu, X; Lu, W; Niu, Y, 2012) |
| "Experiments were performed in freshly harvested aortas from untreated animals and rats fed with oxonic acid (hyperuricemia), and compared to hyperuricemic rats treated with either allopurinol, benzbromarone or arginine." | 3.77 | Hyperuricemia attenuates aortic nitric oxide generation, through inhibition of arginine transport, in rats. ( Chernichovski, T; Engel, A; Grupper, A; Hillel, O; Schwartz, D; Schwartz, IF, 2011) |
| "In this study, the antihyperuricemic effect of Acacia confusa heartwood extracts and their phytochemicals on potassium oxonate (PO)-induced acute hyperuricemia was investigated for the first time." | 3.76 | Phytochemicals from Acacia confusa heartwood extracts reduce serum uric acid levels in oxonate-induced mice: their potential use as xanthine oxidase inhibitors. ( Chang, ST; Chen, CS; Hsu, CA; Huang, CC; Tung, YT; Yang, SC, 2010) |
| "Hyperuricemia may play a role in the pathogenesis of cardiovascular disease, but uric acid is also a significant antioxidant." | 3.75 | Hyperuricemia, oxidative stress, and carotid artery tone in experimental renal insufficiency. ( Eräranta, A; Jolma, P; Kalliovalkama, J; Kurra, V; Moilanen, E; Mustonen, J; Myllymäki, J; Niemelä, O; Pörsti, I; Riutta, A; Tahvanainen, A; Vehmas, TI, 2009) |
| "As oxonic acid diet increased plasma renin activity, plasma aldosterone, and urine K to Na ratio, these changes may play a significant role in the harmful cardiovascular actions of hyperuricemia." | 3.74 | Oxonic acid-induced hyperuricemia elevates plasma aldosterone in experimental renal insufficiency. ( Eräranta, A; Kööbi, P; Kurra, V; Lakkisto, P; Mustonen, JT; Niemelä, OJ; Pörsti, IH; Tahvanainen, AM; Tikkanen, I; Vehmas, TI, 2008) |
| "In rats with hyperuricemia induced by 2% oxonic acid and 0." | 3.74 | Activation of ATP-sensitive potassium channels protects vascular endothelial cells from hypertension and renal injury induced by hyperuricemia. ( Chen, K; Cui, WY; Liu, GS; Long, CL; Pan, ZY; Qin, XC; Wang, H; Zhang, YF, 2008) |
| " Single-dose treatment with UA, as well as acute hyperuricemia induced by the inhibition of uricase, caused a robust mobilization of EPCs, whereas administration of adenosine or inosine seemed to lack this effect." | 3.74 | Uric acid heralds ischemic tissue injury to mobilize endothelial progenitor cells. ( Chintala, S; Gobe, GG; Goligorsky, MS; Patschan, D; Patschan, S, 2007) |
| "The effect of febuxostat (Fx), a non-purine and selective xanthine oxidase inhibitor, on glomerular microcirculatory changes in 5/6 nephrectomy (5/6 Nx) Wistar rats with and without oxonic acid (OA)-induced hyperuricemia was evaluated." | 3.74 | Effect of febuxostat on the progression of renal disease in 5/6 nephrectomy rats with and without hyperuricemia. ( Avila-Casado, C; Franco, M; Johnson, RJ; Sánchez-Lozada, LG; Soto, V; Tapia, E; Wessale, JL; Zhao, L, 2008) |
| " We evaluated the hypouricemic effect of propolis from China on hyperuricemia induced by the uricase inhibitor, oxonic acid (500 mg/kg p." | 3.73 | [Xanthine oxidase inhibitory activity and hypouricemia effect of propolis in rats]. ( Nishioka, N; Tsuji, T; Yoshizumi, K, 2005) |
| "The effects of acacetin (1) and 4,5-O-dicaffeoylquinic acid methyl ester (2), compounds contained in the flowers of Chrysanthemum sinense SABINE, on the serum uric acid level were investigated using the rats pretreated with the uricase inhibitor potassium oxonate as an animal model for hyperuricemia." | 3.73 | Hypouricemic effects of acacetin and 4,5-o-dicaffeoylquinic acid methyl ester on serum uric acid levels in potassium oxonate-pretreated rats. ( Awale, S; Kadota, S; Matsumoto, K; Murakami, Y; Nguyen, MT; Shi, L; Tezuka, Y; Tran, QL; Ueda, JY; Zaidi, SF, 2005) |
| "Hyperuricemia is the primary cause of gouty arthritis and other metabolic disorders." | 1.62 | Eggshell Membrane Ameliorates Hyperuricemia by Increasing Urate Excretion in Potassium Oxonate-Injected Rats. ( Kim, DS; Sung, YY, 2021) |
| " However, BBR exhibits low bioavailability due to its extensive metabolism and limited absorption." | 1.62 | Berberrubine attenuates potassium oxonate- and hypoxanthine-induced hyperuricemia by regulating urate transporters and JAK2/STAT3 signaling pathway. ( Chen, J; Huang, Z; Jiang, L; Li, Y; Lin, G; Lin, Z; Liu, Y; Mai, L; Su, Z; Xie, J; Xu, L; Yu, Q, 2021) |
| "Inflammation is an important pathological feature of hyperuricemia, which in turn aggravates hyperuricemia." | 1.62 | Astaxanthin attenuated hyperuricemia and kidney inflammation by inhibiting uric acid synthesis and the NF-κ B/NLRP3 signaling pathways in potassium oxonate and hypoxanthine-induced hyperuricemia mice. ( Chen, Y; Liu, T; Yang, Z; Yuan, F; Zhang, L; Zhang, S; Zhou, X; Zhuang, J, 2021) |
| "Potassium oxonate was used to induce HUA in model rats, who were then administered WPH for 21 days." | 1.62 | Anti-hyperuricemic and nephroprotective effects of whey protein hydrolysate in potassium oxonate induced hyperuricemic rats. ( Chen, H; Guan, K; Ma, Y; Qi, X; Wang, R, 2021) |
| "Currently, the treatment of gout mainly includes two basic methods: reducing uric acid and alleviating inflammation." | 1.56 | Development of novel NLRP3-XOD dual inhibitors for the treatment of gout. ( Ha, EH; Hu, Q; Li, H; Li, Z; Pang, J; Tian, S; Wang, W; Zhou, M, 2020) |
| "Although hyperuricemia has been shown to be associated with the progression of cardiovascular disorder and chronic kidney disease (CKD), there is conflicting evidence as to whether xanthine oxidase (XO) inhibitors confer organ protection besides lowering serum urate levels." | 1.56 | Cardio-renal protective effect of the xanthine oxidase inhibitor febuxostat in the 5/6 nephrectomy model with hyperuricemia. ( Hayama, Y; Kuribayashi-Okuma, E; Morimoto, C; Omizo, H; Shibata, S; Tamura, Y; Uchida, S; Ueno, M, 2020) |
| "Hyperuricemia is an important risk factor of chronic kidney disease, metabolic syndrome and cardiovascular disease." | 1.56 | The Time-Feature of Uric Acid Excretion in Hyperuricemia Mice Induced by Potassium Oxonate and Adenine. ( Bao, R; Chen, Q; Liu, L; Liu, M; Wang, D; Wang, T; Wen, S; Yu, H; Zhang, Y, 2020) |
| "Hyperuricemia is an independent risk factor for chronic kidney disease (CKD)." | 1.56 | Pharmacological inhibition of fatty acid-binding protein 4 alleviated kidney inflammation and fibrosis in hyperuricemic nephropathy. ( Feng, Y; Fu, P; Guo, F; Huang, R; Liao, D; Ma, L; Shi, M; Zeng, X, 2020) |
| "Gout that caused by hyperuricemia affects human health seriously and more efficient drugs are urgently required clinically." | 1.51 | New Rice-Derived Short Peptide Potently Alleviated Hyperuricemia Induced by Potassium Oxonate in Rats. ( Bian, W; Hu, Y; Liu, N; Meng, B; Sun, J; Wang, S; Wang, Y; Xiong, Z; Yang, M; Yang, X; Yin, S; Zeng, L, 2019) |
| "Uric acid (UA) and XOD were evaluated in the serum, urine, and liver of the mice." | 1.51 | Effects of ChondroT on potassium Oxonate-induced Hyperuricemic mice: downregulation of xanthine oxidase and urate transporter 1. ( Choi, CH; Choi, CY; Kang, BY; Kim, JR; Kim, SJ; Kim, YR; Na, CS; Oh, DR, 2019) |
| "Thus, AE may be a potential treatment for hyperuricemia and gout." | 1.51 | Anti-hyperuricemic effect of Alpinia oxyphylla seed extract by enhancing uric acid excretion in the kidney. ( Kim, DS; Kim, JS; Lee, S; Lee, YS; Son, E; Sung, YY; Yuk, HJ, 2019) |
| "Hyperuricemia is highly prevalent and especially common in subjects with metabolic, cardiovascular and renal diseases." | 1.48 | Probiotic supplements prevented oxonic acid-induced hyperuricemia and renal damage. ( Blas-Marron, MG; Frank, DN; García-Arroyo, FE; Gonzaga, G; Ir, D; Irvin, A; Johnson, RJ; Muñoz-Jiménez, I; Ranganathan, N; Ranganathan, P; Robertson, CE; Sánchez-Lozada, LG; Silverio, O; Soto, V; Tapia, E; Vyas, U, 2018) |
| "sinensis) has been used to treat hyperuricemia and gout." | 1.48 | Anti-hyperuricemic and nephroprotective effects of extracts from Chaenomeles sinensis (Thouin) Koehne in hyperuricemic mice. ( Barba, FJ; He, J; Li, S; Lorenzo, JM; Zhan, S; Zhang, R; Zhu, Z, 2018) |
| "Although hyperuricemia is shown to accelerate chronic kidney disease, the mechanisms remain unclear." | 1.46 | Podocyte Injury and Albuminuria in Experimental Hyperuricemic Model Rats. ( Asakawa, S; Hosoyamada, M; Kumagai, T; Morimoto, C; Nakamura, T; Shibata, S; Shiraishi, T; Tamura, Y; Uchida, S, 2017) |
| "Hyperuricemia is a risk factor for not only gout, but also to a variety of disorders that affect the vital organ systems of the human body." | 1.43 | Antihyperuricemic effects of thiadiazolopyrimidin-5-one analogues in oxonate treated rats. ( Gopal, S; Rangappa, KS; Sathisha, KR, 2016) |
| " However, the pharmacokinetic studies in rats showed that its oral bioavailability was only 1." | 1.43 | Hypouricaemic action of mangiferin results from metabolite norathyriol via inhibiting xanthine oxidase activity. ( Feng, GH; Gao, LH; Li, L; Liu, HY; Liu, J; Liu, X; Niu, Y, 2016) |
| " According to ADME (absorption, distribution, metabolism, and excretion) simulation in silico, flazin had good oral bioavailability in vivo." | 1.43 | Effect of Soy Sauce on Serum Uric Acid Levels in Hyperuricemic Rats and Identification of Flazin as a Potent Xanthine Oxidase Inhibitor. ( Li, H; Lin, L; Su, G; Wang, Y; Zhao, M, 2016) |
| "01); and suggested WECM may interact with URAT1." | 1.43 | Actions of water extract from Cordyceps militaris in hyperuricemic mice induced by potassium oxonate combined with hypoxanthine. ( Chen, D; Chen, S; Feng, D; Jiao, C; Shuai, O; Su, J; Xie, Y; Yong, T; Zhang, M, 2016) |
| "Hyperuricemia is an independent risk factor for chronic kidney disease and cardiovascular disease." | 1.42 | Chinese Herbal Formulas Si-Wu-Tang and Er-Miao-San Synergistically Ameliorated Hyperuricemia and Renal Impairment in Rats Induced by Adenine and Potassium Oxonate. ( Gui, D; Guo, Y; Jiang, Q; Wang, N, 2015) |
| "Hyperuricemia is a biochemical hallmark of gout, renal urate lithiasis, and inherited purine disorders, and may be a result of enormous ATP breakdown or purine release as a result of cardiovascular disease, hypertension, kidney disease, eclampsia, obesity, metabolic syndrome, psoriasis, tumor lysis syndrome, or intense physical training." | 1.40 | Effect of commercial or depurinized milk on rat liver growth-regulatory kinases, nuclear factor-kappa B, and endonuclease in experimental hyperuricemia: comparison with allopurinol therapy. ( Andjelkovic, T; Chiesa, LM; Cvetkovic, T; Jevtovic-Stoimenov, T; Kocic, G; Kocic, H; Nikolic, G; Nikolic, R; Panseri, S; Pavlovic, R; Sokolovic, D; Stojanovic, S; Veljkovic, A, 2014) |
| "Chlorogenic acid is a superoxide radical scavenger with weak xanthine oxidase inhibitory activity." | 1.40 | In vitro and in vivo studies on adlay-derived seed extracts: phenolic profiles, antioxidant activities, serum uric acid suppression, and xanthine oxidase inhibitory effects. ( Dong, Y; Lin, L; Su, G; Sun-Waterhouse, D; Wang, X; Zhao, M; Zhu, D, 2014) |
| "Hyperuricemia is related to a variety of pathologies, including chronic kidney disease (CKD)." | 1.39 | Hyperuricemia influences tryptophan metabolism via inhibition of multidrug resistance protein 4 (MRP4) and breast cancer resistance protein (BCRP). ( Dankers, AC; Dijkman, HB; Hoenderop, JG; Masereeuw, R; Mutsaers, HA; Russel, FG; Sweep, FC; van den Heuvel, LP, 2013) |
| " The effects of casein or soya protein combined with palm or safflower-seed oil on various serum parameters and renal histology were investigated on hyperuricaemic rats." | 1.36 | Relative efficacy of casein or soya protein combined with palm or safflower-seed oil on hyperuricaemia in rats. ( Chiou, HY; Lai, SH; Lo, HC; Wang, YH; Yang, Y, 2010) |
| "Mangiferin was found to down-regulate mRNA and protein levels of urate transporter 1 (mURAT1) and glucose transporter 9 (mGLUT9), as well as up-regulate organic anion transporter 1 (mOAT1) in the kidney of hyperuricemic mice." | 1.36 | [Mangiferin promotes uric acid excretion and kidney function improvement and modulates related renal transporters in hyperuricemic mice]. ( Hu, QH; Kong, LD; Wang, Y; Zhang, X, 2010) |
| " The hyperuricemic mice were oral administrated cinnamaldehyde at a dosage of 150 mg/kg, the uric acid value in serum was reduced from 5." | 1.35 | Essential oil from leaves of Cinnamomum osmophloeum acts as a xanthine oxidase inhibitor and reduces the serum uric acid levels in oxonate-induced mice. ( Chang, ST; Chu, FH; Liao, JW; Wang, SY; Yang, CW; Zhen, WW, 2008) |
| " The mechanism by which uric acid reduces the bioavailability of intrarenal nitric oxide is not known." | 1.35 | Role of oxidative stress in the renal abnormalities induced by experimental hyperuricemia. ( Avila-Casado, C; Franco, M; Johnson, RJ; Nakagawa, T; Rodríguez-Iturbe, B; Sánchez-Lozada, LG; Sautin, YY; Soto, V; Tapia, E, 2008) |
| " We therefore studied the effect of acute and chronic administration of l-arginine (a substrate for endothelial nitric oxide synthase) on the renal hemodynamic and vascular structural alterations induced by HU." | 1.34 | Effects of acute and chronic L-arginine treatment in experimental hyperuricemia. ( Avila-Casado, C; Franco, M; Herrera-Acosta, J; Johnson, RJ; López-Molina, R; Nakagawa, T; Nepomuceno, T; Sánchez-Lozada, LG; Soto, V; Tapia, E, 2007) |
| "Hyperuricemia is associated with a number of pathological conditions such as gout." | 1.33 | The dual actions of morin (3,5,7,2',4'-pentahydroxyflavone) as a hypouricemic agent: uricosuric effect and xanthine oxidase inhibitory activity. ( Cheng, CH; Fong, WP; Yu, Z, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 22 (15.71) | 29.6817 |
| 2010's | 78 (55.71) | 24.3611 |
| 2020's | 40 (28.57) | 2.80 |
| Authors | Studies |
|---|---|
| Rocić, B | 1 |
| Vucić-Lovrencić, M | 1 |
| Poje, N | 1 |
| Poje, M | 1 |
| Bertuzzi, F | 1 |
| Chen, J | 4 |
| Xu, L | 3 |
| Jiang, L | 3 |
| Wu, Y | 2 |
| Wei, L | 1 |
| Wu, X | 3 |
| Xiao, S | 1 |
| Liu, Y | 9 |
| Gao, C | 2 |
| Cai, J | 2 |
| Su, Z | 4 |
| Zhang, CL | 1 |
| Zhang, JJ | 1 |
| Zhu, QF | 1 |
| Guan, HY | 1 |
| Yang, YX | 1 |
| He, X | 1 |
| Fu, Y | 1 |
| Chen, TX | 1 |
| Dong, L | 1 |
| Yang, XS | 1 |
| Tang, KF | 1 |
| Xu, GB | 1 |
| Liao, SG | 1 |
| Sung, YY | 2 |
| Kim, DS | 2 |
| Lin, G | 1 |
| Yu, Q | 1 |
| Huang, Z | 1 |
| Mai, L | 1 |
| Xie, J | 2 |
| Li, Y | 5 |
| Lin, Z | 1 |
| Zhuang, J | 1 |
| Zhou, X | 3 |
| Liu, T | 2 |
| Zhang, S | 2 |
| Yuan, F | 1 |
| Zhang, L | 6 |
| Yang, Z | 2 |
| Chen, Y | 6 |
| Zhang, TJ | 1 |
| Zhang, Y | 5 |
| Zhang, ZH | 1 |
| Wang, ZR | 1 |
| Zhang, X | 5 |
| Hu, SS | 1 |
| Lu, PF | 1 |
| Guo, S | 1 |
| Meng, FH | 1 |
| Hu, BY | 1 |
| Zhao, YL | 1 |
| Ma, DY | 1 |
| Xiang, ML | 1 |
| Zhao, LX | 1 |
| Luo, XD | 1 |
| ALRashdi, BM | 1 |
| Elgebaly, HA | 1 |
| Germoush, MO | 1 |
| Qarmush, MM | 1 |
| Azab, MS | 1 |
| Alruhaimi, RS | 1 |
| Ahmeda, AF | 1 |
| Abukhalil, MH | 1 |
| Kamel, EM | 1 |
| Arab, HH | 1 |
| Alzoghaibi, MA | 1 |
| Alotaibi, MF | 1 |
| Mahmoud, AM | 1 |
| Yong, T | 3 |
| Liang, D | 2 |
| Chen, S | 3 |
| Xiao, C | 1 |
| Gao, X | 1 |
| Wu, Q | 1 |
| Xie, Y | 4 |
| Huang, L | 1 |
| Hu, H | 1 |
| Li, X | 1 |
| Cai, M | 1 |
| Wang, CC | 1 |
| Li, YL | 1 |
| Chiu, PY | 1 |
| Chen, C | 1 |
| Chen, HC | 1 |
| Chen, FA | 1 |
| Guan, H | 1 |
| Lin, H | 4 |
| Wang, X | 6 |
| Xu, Y | 1 |
| Zheng, Y | 2 |
| Diao, X | 2 |
| Ye, Z | 1 |
| Xiao, J | 1 |
| Qu, C | 1 |
| Lin, Y | 3 |
| Yi, X | 1 |
| Zeng, H | 1 |
| Kurra, V | 4 |
| Eräranta, A | 4 |
| Paavonen, T | 1 |
| Honkanen, T | 1 |
| Myllymäki, J | 2 |
| Riutta, A | 2 |
| Tikkanen, I | 2 |
| Lakkisto, P | 2 |
| Mustonen, J | 3 |
| Pörsti, I | 3 |
| Xie, D | 1 |
| Shen, Y | 1 |
| Su, E | 1 |
| Du, L | 1 |
| Wei, D | 1 |
| Zhong, L | 1 |
| Gong, S | 1 |
| Yan, F | 1 |
| Xie, Q | 1 |
| Luo, X | 2 |
| Zhou, L | 2 |
| Wang, S | 6 |
| Yuan, J | 2 |
| Chang, Z | 2 |
| Hu, Q | 3 |
| Huang, Y | 2 |
| Wang, B | 2 |
| Gao, Y | 2 |
| Wang, Z | 2 |
| Cui, Y | 2 |
| Li, C | 3 |
| Zhao, Y | 1 |
| Ma, S | 1 |
| Lin, F | 1 |
| An, J | 1 |
| Ota-Kontani, A | 1 |
| Hirata, H | 1 |
| Ogura, M | 1 |
| Tsuchiya, Y | 1 |
| Harada-Shiba, M | 1 |
| Dera, AA | 1 |
| Rajagopalan, P | 1 |
| Alfhili, MA | 1 |
| Ahmed, I | 1 |
| Chandramoorthy, HC | 1 |
| Xu, WH | 1 |
| Wang, HT | 1 |
| Sun, Y | 1 |
| Xue, ZC | 1 |
| Liang, ML | 1 |
| Su, WK | 1 |
| Wang, W | 2 |
| Pang, J | 3 |
| Ha, EH | 1 |
| Zhou, M | 1 |
| Li, Z | 5 |
| Tian, S | 1 |
| Li, H | 4 |
| Morimoto, C | 3 |
| Tamura, Y | 3 |
| Asakawa, S | 2 |
| Kuribayashi-Okuma, E | 2 |
| Nemoto, Y | 1 |
| Li, J | 6 |
| Murase, T | 1 |
| Nakamura, T | 2 |
| Hosoyamada, M | 2 |
| Uchida, S | 3 |
| Shibata, S | 3 |
| Gao, J | 2 |
| Liu, X | 7 |
| Zhang, B | 2 |
| Mao, Q | 1 |
| Zhang, Z | 1 |
| Zou, Q | 1 |
| Dai, X | 1 |
| Bilal, M | 1 |
| Ahmad, S | 1 |
| Rehman, T | 1 |
| Abbasi, WM | 1 |
| Ghauri, AO | 1 |
| Arshad, MA | 1 |
| Ayaz, S | 1 |
| Nawaz, A | 1 |
| Mehmood, A | 1 |
| Zhao, L | 4 |
| Ishaq, M | 1 |
| Usman, M | 1 |
| Zad, OD | 1 |
| Hossain, I | 1 |
| Raka, RN | 1 |
| Naveed, M | 1 |
| Wang, C | 3 |
| Nadeem, M | 1 |
| Omizo, H | 1 |
| Ueno, M | 1 |
| Hayama, Y | 1 |
| Han, B | 1 |
| Gong, M | 1 |
| Qiu, Y | 1 |
| Zou, Z | 1 |
| Wen, S | 1 |
| Wang, D | 1 |
| Yu, H | 2 |
| Liu, M | 3 |
| Chen, Q | 2 |
| Bao, R | 1 |
| Liu, L | 2 |
| Wang, T | 3 |
| Zeng, Y | 1 |
| Ma, Y | 3 |
| Mao, J | 1 |
| Shi, M | 1 |
| Guo, F | 1 |
| Liao, D | 1 |
| Huang, R | 1 |
| Feng, Y | 1 |
| Zeng, X | 2 |
| Ma, L | 2 |
| Fu, P | 1 |
| Zhao, Z | 2 |
| Yang, Y | 3 |
| Li, L | 7 |
| Jiang, Y | 2 |
| Lin, C | 1 |
| Cao, Y | 2 |
| Zhou, P | 2 |
| Tian, Y | 2 |
| Wu, T | 2 |
| Dhouibi, R | 1 |
| Affes, H | 1 |
| Salem, MB | 1 |
| Moalla, D | 1 |
| Marekchi, R | 1 |
| Charfi, S | 1 |
| Hammami, S | 1 |
| Sahnoun, Z | 1 |
| Jamoussi, K | 1 |
| Zeghal, KM | 1 |
| Ksouda, K | 1 |
| Lin, L | 3 |
| Zhao, M | 4 |
| Peng, A | 1 |
| Zhao, K | 1 |
| Zhao, X | 3 |
| Wang, J | 3 |
| Tang, L | 1 |
| Li, P | 1 |
| Ru, J | 1 |
| Bai, Y | 1 |
| Qi, X | 1 |
| Chen, H | 2 |
| Guan, K | 1 |
| Wang, R | 1 |
| Hu, N | 1 |
| Luo, J | 1 |
| Huang, Q | 1 |
| Wang, YZ | 1 |
| Zhou, C | 1 |
| Zhu, LJ | 1 |
| He, XL | 1 |
| Li, LZ | 1 |
| Zheng, X | 2 |
| Xu, WF | 1 |
| Dong, YJ | 1 |
| Li, B | 1 |
| Yu, QX | 1 |
| Lv, GY | 1 |
| Chen, SH | 1 |
| Lee, MH | 1 |
| Yang, F | 2 |
| Shi, W | 1 |
| Wang, L | 2 |
| Qin, N | 2 |
| Guo, Y | 2 |
| Xu, G | 1 |
| Fang, J | 1 |
| Yu, X | 1 |
| Ma, Q | 2 |
| Shiraishi, T | 1 |
| Kumagai, T | 1 |
| Zhang, HJ | 1 |
| Li, LN | 1 |
| Zhou, J | 1 |
| Yang, QQ | 1 |
| Liu, PG | 1 |
| Xu, P | 1 |
| Liang, WQ | 1 |
| Cheng, L | 1 |
| Zhang, YQ | 1 |
| Pu, JB | 1 |
| Hu, YJ | 1 |
| Chen, L | 1 |
| Lan, Z | 1 |
| Li, ZJ | 1 |
| Dong, XY | 1 |
| Lu, LF | 1 |
| Wang, CL | 1 |
| Wu, F | 1 |
| Zou, Y | 2 |
| Jin, L | 1 |
| Liu, J | 3 |
| Su, Q | 1 |
| Su, H | 1 |
| Nong, Z | 1 |
| Li, D | 2 |
| Chu, S | 1 |
| Liao, L | 1 |
| Zhao, J | 2 |
| Ya, Q | 1 |
| He, F | 1 |
| Lu, W | 2 |
| Wei, B | 1 |
| Wei, G | 1 |
| Chen, N | 1 |
| Wang, K | 1 |
| Hu, L | 1 |
| Chen, JK | 1 |
| Nakashima, A | 1 |
| Yamauchi, A | 1 |
| Matsumoto, J | 1 |
| Dohgu, S | 1 |
| Takata, F | 1 |
| Koga, M | 1 |
| Fukae, J | 1 |
| Tsuboi, Y | 1 |
| Kataoka, Y | 1 |
| Yang, H | 2 |
| Bai, W | 1 |
| Gao, L | 3 |
| Jiang, J | 2 |
| Tang, Y | 1 |
| Niu, Y | 4 |
| García-Arroyo, FE | 3 |
| Gonzaga, G | 1 |
| Muñoz-Jiménez, I | 1 |
| Blas-Marron, MG | 1 |
| Silverio, O | 1 |
| Tapia, E | 7 |
| Soto, V | 6 |
| Ranganathan, N | 1 |
| Ranganathan, P | 1 |
| Vyas, U | 1 |
| Irvin, A | 1 |
| Ir, D | 1 |
| Robertson, CE | 1 |
| Frank, DN | 1 |
| Johnson, RJ | 8 |
| Sánchez-Lozada, LG | 7 |
| He, W | 1 |
| Su, G | 3 |
| Sun-Waterhouse, D | 2 |
| Waterhouse, GIN | 1 |
| Zhang, R | 1 |
| Zhan, S | 2 |
| Li, S | 2 |
| Zhu, Z | 1 |
| He, J | 1 |
| Lorenzo, JM | 1 |
| Barba, FJ | 1 |
| Li, M | 1 |
| Deng, C | 1 |
| Chen, D | 2 |
| Zuo, D | 1 |
| Zhang, G | 1 |
| Xi, D | 1 |
| Rao, Z | 1 |
| Sun, X | 1 |
| Li, Q | 1 |
| Wang, F | 1 |
| Xing, C | 1 |
| Liu, N | 1 |
| Wang, Y | 5 |
| Yang, M | 1 |
| Bian, W | 1 |
| Zeng, L | 1 |
| Yin, S | 1 |
| Xiong, Z | 1 |
| Hu, Y | 1 |
| Meng, B | 1 |
| Sun, J | 1 |
| Yang, X | 1 |
| Oh, DR | 1 |
| Kim, JR | 1 |
| Choi, CY | 1 |
| Choi, CH | 1 |
| Na, CS | 1 |
| Kang, BY | 1 |
| Kim, SJ | 1 |
| Kim, YR | 1 |
| You, W | 1 |
| Che, K | 1 |
| Hou, X | 1 |
| Fei, H | 1 |
| Nishizawa, K | 1 |
| Yoda, N | 1 |
| Morokado, F | 1 |
| Komori, H | 1 |
| Nakanishi, T | 1 |
| Tamai, I | 1 |
| Liang, G | 1 |
| Nie, Y | 1 |
| Chang, Y | 1 |
| Zeng, S | 1 |
| Liang, C | 1 |
| Xiao, D | 1 |
| Zheng, Q | 1 |
| Yu, M | 1 |
| Yang, TH | 1 |
| Yan, DX | 1 |
| Huang, XY | 1 |
| Hou, B | 1 |
| Ma, YB | 1 |
| Peng, H | 1 |
| Zhang, XM | 1 |
| Chen, JJ | 1 |
| Geng, CA | 1 |
| Lee, YS | 1 |
| Yuk, HJ | 1 |
| Son, E | 1 |
| Lee, S | 1 |
| Kim, JS | 1 |
| Chau, YT | 1 |
| Chen, HY | 1 |
| Lin, PH | 1 |
| Hsia, SM | 1 |
| Duan, S | 1 |
| Yuan, X | 2 |
| Liang, J | 2 |
| Hou, S | 1 |
| Zhou, Z | 1 |
| Dong, Y | 2 |
| Zhou, H | 1 |
| Zhao, W | 1 |
| Dankers, AC | 1 |
| Mutsaers, HA | 1 |
| Dijkman, HB | 1 |
| van den Heuvel, LP | 1 |
| Hoenderop, JG | 1 |
| Sweep, FC | 1 |
| Russel, FG | 1 |
| Masereeuw, R | 1 |
| Hu, QH | 5 |
| Zhu, JX | 3 |
| Ji, J | 1 |
| Wei, LL | 1 |
| Miao, MX | 1 |
| Ji, H | 1 |
| Chen, YS | 1 |
| Zhu, Q | 1 |
| Kong, LD | 9 |
| Wu, XH | 4 |
| Yu, CH | 2 |
| Zhang, CF | 1 |
| Anderson, S | 2 |
| Zhang, YW | 4 |
| Chen, JW | 1 |
| Zhou, Y | 2 |
| Xue, ZY | 1 |
| Guo, J | 1 |
| Zhou, LY | 1 |
| Jiang, JM | 1 |
| Kocic, G | 1 |
| Pavlovic, R | 1 |
| Nikolic, G | 1 |
| Veljkovic, A | 1 |
| Panseri, S | 1 |
| Chiesa, LM | 1 |
| Andjelkovic, T | 1 |
| Jevtovic-Stoimenov, T | 1 |
| Sokolovic, D | 1 |
| Cvetkovic, T | 1 |
| Stojanovic, S | 1 |
| Kocic, H | 1 |
| Nikolic, R | 1 |
| Su, J | 2 |
| Wei, Y | 1 |
| Ji, Y | 1 |
| Zhu, D | 1 |
| Yuan, Y | 1 |
| Wang, CZ | 1 |
| Zhang, J | 4 |
| Wang, SQ | 3 |
| Han, L | 1 |
| Yuan, CS | 1 |
| Ruan, JL | 1 |
| Wang, MX | 1 |
| Liu, YL | 3 |
| Zhang, DM | 2 |
| Lemos Lima, Rde C | 1 |
| Ferrari, FC | 1 |
| de Souza, MR | 2 |
| de Sá Pereira, BM | 1 |
| de Paula, CA | 2 |
| Saúde-Guimarães, DA | 2 |
| Kodithuwakku, ND | 1 |
| Feng, YD | 1 |
| Zhang, YY | 1 |
| Pan, M | 1 |
| Fang, WR | 1 |
| Li, YM | 1 |
| Vehmas, T | 1 |
| Jokihaara, J | 1 |
| Pirttiniemi, P | 1 |
| Ruskoaho, H | 1 |
| Tokola, H | 1 |
| Niemelä, O | 2 |
| Yan, M | 1 |
| An, YT | 1 |
| Wu, ZZ | 1 |
| Cristóbal-García, M | 1 |
| Osorio, H | 1 |
| Arellano-Buendía, AS | 1 |
| Madero, M | 2 |
| Rodríguez-Iturbe, B | 2 |
| Pedraza-Chaverrí, J | 1 |
| Correa, F | 1 |
| Zazueta, C | 1 |
| Lozada, LG | 1 |
| Hou, PY | 1 |
| Mi, C | 1 |
| He, Y | 1 |
| Yu, F | 1 |
| Kong, X | 1 |
| Chen, G | 1 |
| Tan, ML | 1 |
| Li, KK | 1 |
| Leung, PC | 1 |
| Ko, CH | 1 |
| Tanaka, R | 1 |
| Miyata, Y | 1 |
| Minakuchi, N | 1 |
| Murakami, A | 1 |
| Sakazaki, F | 1 |
| Jiang, Q | 1 |
| Gui, D | 1 |
| Wang, N | 1 |
| Hui, W | 1 |
| Yongliang, Y | 1 |
| Yongde, C | 1 |
| Guo, L | 1 |
| Zhonglin, Y | 1 |
| Hui, J | 1 |
| Qinghua, H | 1 |
| Tung, YT | 2 |
| Lin, LC | 1 |
| Ho, ST | 1 |
| Lin, CY | 1 |
| Chuang, HL | 1 |
| Chiu, CC | 1 |
| Huang, CC | 2 |
| Wu, JH | 1 |
| Li, HT | 1 |
| Wang, LL | 1 |
| Trachtman, H | 1 |
| Trasande, L | 1 |
| Wang, PX | 1 |
| Liu, JM | 1 |
| Sathisha, KR | 1 |
| Gopal, S | 1 |
| Rangappa, KS | 1 |
| Liu, HY | 1 |
| Gao, LH | 1 |
| Feng, GH | 1 |
| Etani, R | 1 |
| Kataoka, T | 1 |
| Kanzaki, N | 1 |
| Sakoda, A | 1 |
| Tanaka, H | 1 |
| Ishimori, Y | 1 |
| Mitsunobu, F | 1 |
| Yamaoka, K | 1 |
| Wang, M | 1 |
| Zhang, N | 1 |
| Yoon, IS | 1 |
| Park, DH | 1 |
| Ki, SH | 1 |
| Cho, SS | 1 |
| Jhang, JJ | 1 |
| Ong, JW | 1 |
| Lu, CC | 1 |
| Hsu, CL | 1 |
| Lin, JH | 1 |
| Liao, JW | 2 |
| Yen, GC | 1 |
| Zhang, M | 1 |
| Shuai, O | 1 |
| Jiao, C | 1 |
| Feng, D | 1 |
| Hongyan, L | 1 |
| Suling, W | 1 |
| Weina, Z | 1 |
| Yajie, Z | 1 |
| Jie, R | 1 |
| Tang, DH | 1 |
| Ye, YS | 1 |
| Wang, CY | 1 |
| Li, ZL | 1 |
| Zheng, H | 1 |
| Ma, KL | 1 |
| Tahvanainen, AM | 1 |
| Vehmas, TI | 2 |
| Kööbi, P | 1 |
| Niemelä, OJ | 1 |
| Mustonen, JT | 1 |
| Pörsti, IH | 1 |
| Wang, SY | 1 |
| Yang, CW | 1 |
| Zhen, WW | 1 |
| Chu, FH | 1 |
| Chang, ST | 2 |
| Chen, R | 1 |
| Shang, Y | 1 |
| Jiao, B | 1 |
| Huang, C | 1 |
| Avila-Casado, C | 4 |
| Sautin, YY | 1 |
| Nakagawa, T | 3 |
| Franco, M | 4 |
| Long, CL | 1 |
| Qin, XC | 1 |
| Pan, ZY | 1 |
| Chen, K | 1 |
| Zhang, YF | 1 |
| Cui, WY | 1 |
| Liu, GS | 1 |
| Wang, H | 1 |
| Jolma, P | 1 |
| Moilanen, E | 1 |
| Tahvanainen, A | 1 |
| Kalliovalkama, J | 1 |
| Lo, HC | 1 |
| Wang, YH | 1 |
| Chiou, HY | 1 |
| Lai, SH | 1 |
| Jiao, RQ | 1 |
| Lv, YZ | 2 |
| Hsu, CA | 1 |
| Chen, CS | 1 |
| Yang, SC | 1 |
| Schwartz, IF | 1 |
| Grupper, A | 2 |
| Chernichovski, T | 1 |
| Hillel, O | 1 |
| Engel, A | 1 |
| Schwartz, D | 1 |
| Hwa, KS | 1 |
| Chung, DM | 1 |
| Chung, YC | 1 |
| Chun, HK | 1 |
| Li, JM | 1 |
| Xie, YC | 1 |
| B-Rao, C | 1 |
| Kulkarni-Almeida, A | 1 |
| Katkar, KV | 1 |
| Khanna, S | 1 |
| Ghosh, U | 1 |
| Keche, A | 1 |
| Shah, P | 1 |
| Srivastava, A | 1 |
| Korde, V | 1 |
| Nemmani, KV | 1 |
| Deshmukh, NJ | 1 |
| Dixit, A | 1 |
| Brahma, MK | 1 |
| Bahirat, U | 1 |
| Doshi, L | 1 |
| Sharma, R | 1 |
| Sivaramakrishnan, H | 1 |
| Hua, J | 1 |
| Huang, P | 1 |
| Zhu, CM | 1 |
| Pereira de Resende, ML | 1 |
| Grabe-Guimarães, A | 1 |
| de Souza Filho, JD | 1 |
| Yi, LT | 1 |
| Su, DX | 1 |
| Dong, JF | 1 |
| Li, CF | 1 |
| Shi, YW | 1 |
| Wang, CP | 1 |
| Hong, Y | 1 |
| Hou, CW | 1 |
| Lee, YC | 1 |
| Hung, HF | 1 |
| Fu, HW | 1 |
| Jeng, KC | 1 |
| Silva, CR | 1 |
| Fröhlich, JK | 1 |
| Oliveira, SM | 1 |
| Cabreira, TN | 1 |
| Rossato, MF | 1 |
| Trevisan, G | 1 |
| Froeder, AL | 1 |
| Bochi, GV | 1 |
| Moresco, RN | 1 |
| Athayde, ML | 1 |
| Ferreira, J | 1 |
| Cristóbal, M | 1 |
| Monroy-Sánchez, F | 1 |
| Pacheco, U | 1 |
| Lanaspa, MA | 1 |
| Roncal-Jiménez, CA | 1 |
| Cruz-Robles, D | 1 |
| Ishimoto, T | 1 |
| Yang, C | 1 |
| Cheng, CH | 2 |
| Yoshizumi, K | 1 |
| Nishioka, N | 1 |
| Tsuji, T | 1 |
| Yu, Z | 1 |
| Fong, WP | 1 |
| Mo, SF | 2 |
| Pan, Y | 1 |
| Nguyen, MT | 1 |
| Awale, S | 1 |
| Tezuka, Y | 1 |
| Shi, L | 1 |
| Zaidi, SF | 1 |
| Ueda, JY | 1 |
| Tran, QL | 1 |
| Murakami, Y | 1 |
| Matsumoto, K | 1 |
| Kadota, S | 1 |
| Mazzali, M | 1 |
| Kang, DH | 1 |
| Herrera-Acosta, J | 2 |
| Chen, GL | 1 |
| Wei, W | 1 |
| Xu, SY | 1 |
| Umamaheswari, M | 1 |
| AsokKumar, K | 1 |
| Somasundaram, A | 1 |
| Sivashanmugam, T | 1 |
| Subhadradevi, V | 1 |
| Ravi, TK | 1 |
| López-Molina, R | 1 |
| Nepomuceno, T | 1 |
| Patschan, D | 1 |
| Patschan, S | 1 |
| Gobe, GG | 1 |
| Chintala, S | 1 |
| Goligorsky, MS | 1 |
| Zhou, F | 1 |
| Sarawek, S | 1 |
| Feistel, B | 1 |
| Pischel, I | 1 |
| Butterweck, V | 1 |
| Huang, CG | 1 |
| Shang, YJ | 1 |
| Zhang, JR | 1 |
| Li, WJ | 1 |
| Jiao, BH | 1 |
| Wessale, JL | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Three Arms, Randomized, Double-blind Controlled Trial of the Efficacy of Amway Uric Acid Lowering Product on Hyperuricemia[NCT06084585] | 180 participants (Anticipated) | Interventional | 2023-10-23 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for oxonic acid and Hyperuricemia
| Article | Year |
|---|---|
Uric acid--a uremic toxin?
Topics: Animals; Arteriosclerosis; Biomarkers; Enzyme Inhibitors; Humans; Hypertension; Hypertrophy; Hyperur | 2006 |
139 other studies available for oxonic acid and Hyperuricemia
| Article | Year |
|---|---|
Uric acid may inhibit glucose-induced insulin secretion via binding to an essential arginine residue in rat pancreatic beta-cells.
Topics: Animals; Arginine; Glucose; Hyperuricemia; In Vitro Techniques; Insulin; Insulin Secretion; Islets o | 2005 |
Topics: Acute Kidney Injury; Animals; Animals, Outbred Strains; Carrier Proteins; Cytokines; Dietary Supplem | 2021 |
Antihyperuricemia and antigouty arthritis effects of Persicaria capitata herba in mice.
Topics: Animals; Arthritis, Gouty; Hyperuricemia; Mice; Oxonic Acid; Plant Extracts; Uric Acid; Xanthine Oxi | 2021 |
Eggshell Membrane Ameliorates Hyperuricemia by Increasing Urate Excretion in Potassium Oxonate-Injected Rats.
Topics: Animals; Egg Shell; Humans; Hyperuricemia; Inflammation; Injections; Kidney; Kidney Function Tests; | 2021 |
Berberrubine attenuates potassium oxonate- and hypoxanthine-induced hyperuricemia by regulating urate transporters and JAK2/STAT3 signaling pathway.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily G, Member 2; Berberine; Blood Urea Nitrogen; Ch | 2021 |
Astaxanthin attenuated hyperuricemia and kidney inflammation by inhibiting uric acid synthesis and the NF-κ B/NLRP3 signaling pathways in potassium oxonate and hypoxanthine-induced hyperuricemia mice.
Topics: Animals; Antioxidants; Hyperuricemia; Hypoxanthine; Inflammation; Kidney; Male; Mice; Mice, Inbred I | 2021 |
Discovery of 4-(phenoxymethyl)-1H-1,2,3-triazole derivatives as novel xanthine oxidase inhibitors.
Topics: Animals; Dose-Response Relationship, Drug; Drug Discovery; Enzyme Inhibitors; Hyperuricemia; Ligands | 2022 |
Anti-hyperuricemic bioactivity of Alstonia scholaris and its bioactive triterpenoids in vivo and in vitro.
Topics: Alstonia; Animals; Cell Line; Disease Models, Animal; Dose-Response Relationship, Drug; Humans; Hype | 2022 |
A flavonoid-rich fraction of Monolluma quadrangula inhibits xanthine oxidase and ameliorates potassium oxonate-induced hyperuricemia in rats.
Topics: Animals; Catalase; Creatinine; Cytokines; Flavonoids; Hyperuricemia; Inflammation; Kidney; Molecular | 2022 |
Caffeic acid phenethyl ester alleviated hypouricemia in hyperuricemic mice through inhibiting XOD and up-regulating OAT3.
Topics: Animals; Caffeic Acids; Hyperuricemia; Kidney; Mice; Molecular Docking Simulation; Organic Anion Tra | 2022 |
Protective effects of corni fructus extract in mice with potassium oxonate-induced hyperuricemia.
Topics: Animals; Antioxidants; Cornus; Gout; Hyperuricemia; Mice; Oxonic Acid; Plant Extracts; Uric Acid; Xa | 2022 |
Autophagy-dependent Na
Topics: Adenosine Triphosphatases; Adenosine Triphosphate; Animals; Autophagy; Hydroxychloroquine; Hyperuric | 2022 |
Hypouricemic effect of gallic acid, a bioactive compound from
Topics: Adenosine Deaminase; Adenosine Triphosphatases; Animals; Creatinine; Cyclooxygenase 2; Cystatins; Ga | 2022 |
Moderate hyperuricaemia ameliorated kidney damage in a low-renin model of experimental renal insufficiency.
Topics: Animals; Fibrosis; Hyperuricemia; Inflammation; Kidney; Kidney Diseases; Nephrectomy; Oxonic Acid; R | 2023 |
Anti-Hyperuricemic, Nephroprotective, and Gut Microbiota Regulative Effects of Separated Hydrolysate of α-Lactalbumin on Potassium Oxonate- and Hypoxanthine-Induced Hyperuricemic Mice.
Topics: Animals; Gastrointestinal Microbiome; Hyperuricemia; Hypoxanthines; Inflammation; Kidney; Lactalbumi | 2023 |
Oxyberberrubine, a novel liver microsomes-mediated secondary metabolite of berberine, alleviates hyperuricemic nephropathy in mice.
Topics: Animals; Berberine; Hyperuricemia; Kidney; Mice; Microsomes, Liver; NLR Family, Pyrin Domain-Contain | 2023 |
The Therapeutic Effect and the Potential Mechanism of Flavonoids and Phenolics of
Topics: Flavonoids; Hyperuricemia; Kidney; Molecular Docking Simulation; Moringa oleifera; Organic Anion Tra | 2022 |
The Therapeutic Effect and the Potential Mechanism of Flavonoids and Phenolics of
Topics: Flavonoids; Hyperuricemia; Kidney; Molecular Docking Simulation; Moringa oleifera; Organic Anion Tra | 2022 |
The Therapeutic Effect and the Potential Mechanism of Flavonoids and Phenolics of
Topics: Flavonoids; Hyperuricemia; Kidney; Molecular Docking Simulation; Moringa oleifera; Organic Anion Tra | 2022 |
The Therapeutic Effect and the Potential Mechanism of Flavonoids and Phenolics of
Topics: Flavonoids; Hyperuricemia; Kidney; Molecular Docking Simulation; Moringa oleifera; Organic Anion Tra | 2022 |
Paeonia × suffruticosa Andrews leaf extract and its main component apigenin 7-O-glucoside ameliorate hyperuricemia by inhibiting xanthine oxidase activity and regulating renal urate transporters.
Topics: Animals; Apigenin; Creatinine; Glucosides; Gout; Hyperuricemia; Kidney; Malondialdehyde; Mice; Molec | 2023 |
Comprehensive analysis of mechanism underlying hypouricemic effect of glucosyl hesperidin.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily G, Member 2; Glucose Transport Proteins, Facili | 2020 |
Thymoquinone attenuates oxidative stress of kidney mitochondria and exerts nephroprotective effects in oxonic acid-induced hyperuricemia rats.
Topics: Animals; Benzoquinones; Disease Models, Animal; Hyperuricemia; Kidney; Kidney Diseases; Male; Mitoch | 2020 |
Antihyperuricemic and nephroprotective effects of extracts from Orthosiphon stamineus in hyperuricemic mice.
Topics: Animals; Creatinine; Hyperuricemia; Kidney; Liver; Male; Mice; Organic Anion Transporters; Orthosiph | 2020 |
Development of novel NLRP3-XOD dual inhibitors for the treatment of gout.
Topics: Animals; Benzimidazoles; Benzoxazoles; Cell Line; Disease Models, Animal; Gout; Humans; Hyperuricemi | 2020 |
ABCG2 expression and uric acid metabolism of the intestine in hyperuricemia model rat.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily G, Member 2; Hyperuricemia; Intestines; Male; O | 2020 |
Design, synthesis and biological evaluation of 1-alkyl-5/6-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)-1H-indole-3-carbonitriles as novel xanthine oxidase inhibitors.
Topics: Allopurinol; Animals; Catalytic Domain; Cattle; Drug Design; Enzyme Assays; Enzyme Inhibitors; Hyper | 2020 |
Development of herbal formulation of medicinal plants and determination of its antihyperuricemic potential in vitro and in vivo rat's model.
Topics: Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Compounding; Drug Developmen | 2020 |
Uricostatic and uricosuric effect of grapefruit juice in potassium oxonate-induced hyperuricemic mice.
Topics: Animals; Citrus paradisi; Hyperuricemia; Mice; Oxonic Acid; Uric Acid | 2020 |
Cardio-renal protective effect of the xanthine oxidase inhibitor febuxostat in the 5/6 nephrectomy model with hyperuricemia.
Topics: Animals; Cardiotonic Agents; Disease Models, Animal; Febuxostat; Heart; Hyperuricemia; Kidney Diseas | 2020 |
NMR-Based Metabonomic Study Reveals Intervention Effects of Polydatin on Potassium Oxonate-Induced Hyperuricemia in Rats.
Topics: Animals; Blood Urea Nitrogen; Creatinine; Disease Models, Animal; Drugs, Chinese Herbal; Glucosides; | 2020 |
The Time-Feature of Uric Acid Excretion in Hyperuricemia Mice Induced by Potassium Oxonate and Adenine.
Topics: Adenine; Animals; ATP Binding Cassette Transporter, Subfamily G, Member 2; Chromatography, High Pres | 2020 |
Antihyperuricemic efficacy of Scopoletin-loaded Soluplus micelles in yeast extract/potassium oxonate-induced hyperuricemic mice.
Topics: Animals; Gout Suppressants; Hyperuricemia; Kidney; Mice; Micelles; Oxonic Acid; Polyethylene Glycols | 2020 |
Pharmacological inhibition of fatty acid-binding protein 4 alleviated kidney inflammation and fibrosis in hyperuricemic nephropathy.
Topics: Adenine; Animals; Biphenyl Compounds; Cytokines; Fatty Acid-Binding Proteins; Fibrosis; Hepatitis A | 2020 |
Baicalein alleviates hyperuricemia by promoting uric acid excretion and inhibiting xanthine oxidase.
Topics: Animals; Antioxidants; Disease Models, Animal; Enzyme Inhibitors; Flavanones; Glucose Transport Prot | 2021 |
Creation of an adequate animal model of hyperuricemia (acute and chronic hyperuricemia); study of its reversibility and its maintenance.
Topics: Animals; Antioxidants; Biomarkers; Chronic Disease; Creatinine; Disease Models, Animal; Hyperuricemi | 2021 |
Xanthine oxidase inhibitory activity and antihyperuricemic effect of Moringa oleifera Lam. leaf hydrolysate rich in phenolics and peptides.
Topics: Animals; Creatinine; Disease Models, Animal; Flavonoids; Gout Suppressants; Hyperuricemia; Malondial | 2021 |
Withaferin A protects against hyperuricemia induced kidney injury and its possible mechanisms.
Topics: Animals; Apoptosis; Disease Models, Animal; Fibrosis; Hyperuricemia; Kidney; Kidney Diseases; Male; | 2021 |
Anti-hyperuricemic and nephroprotective effects of whey protein hydrolysate in potassium oxonate induced hyperuricemic rats.
Topics: Adenosine Deaminase; Animals; Creatinine; Humans; Hyperuricemia; Kidney; Liver; Male; Oxonic Acid; P | 2021 |
Chlorogenic acid supplementation ameliorates hyperuricemia, relieves renal inflammation, and modulates intestinal homeostasis.
Topics: Animals; Blood Urea Nitrogen; Chlorogenic Acid; Creatinine; Dietary Supplements; Gastrointestinal Mi | 2021 |
Apigenin ameliorates hyperuricemic nephropathy by inhibiting URAT1 and GLUT9 and relieving renal fibrosis via the Wnt/β-catenin pathway.
Topics: Animals; Apigenin; beta Catenin; Creatinine; Dose-Response Relationship, Drug; Fibrosis; Glucose Tra | 2021 |
Effects of Macroporous Resin Extract of Dendrobium officinale Leaves in Rats with Hyperuricemia Induced by Fructose and Potassium Oxonate.
Topics: Adenosine Triphosphate; Animals; Dendrobium; Fructose; Hyperuricemia; Kidney; Oxonic Acid; Plant Ext | 2022 |
Vitamin C alleviates hyperuricemia nephropathy by reducing inflammation and fibrosis.
Topics: Animals; Antioxidants; Ascorbic Acid; Fibrosis; Hyperuricemia; Inflammation; Kidney Diseases; Male; | 2021 |
Lipidomics study of the therapeutic mechanism of Plantaginis Semen in potassium oxonate-induced hyperuricemia rat.
Topics: Animals; Creatinine; Hyperuricemia; Lipid Metabolism; Lipidomics; Oxonic Acid; Psyllium; Rats, Sprag | 2021 |
Podocyte Injury and Albuminuria in Experimental Hyperuricemic Model Rats.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Actins; Albuminuria; Animals; Blood Pressure; Cyclic N-Oxides; Deoxygua | 2017 |
Effects of Gnaphalium affine D. Don on hyperuricemia and acute gouty arthritis.
Topics: Animals; Anti-Inflammatory Agents; Arthritis, Gouty; Chromatography, High Pressure Liquid; Disease M | 2017 |
Polydatin attenuates potassium oxonate-induced hyperuricemia and kidney inflammation by inhibiting NF-κB/NLRP3 inflammasome activation via the AMPK/SIRT1 pathway.
Topics: AMP-Activated Protein Kinases; Animals; Glucosides; Humans; Hyperuricemia; Inflammasomes; Kidney; Ma | 2017 |
Hypouricemic and nephroprotective effects of total flavonoids from the residue of supercritical CO2 extraction of Humulus lupulus in potassium oxonate-induced mice.
Topics: Animals; Carbon Dioxide; Chromatography, Supercritical Fluid; Flavonoids; Humulus; Hyperuricemia; In | 2017 |
Synthesis and bioevaluation of 1-phenyl-pyrazole-4-carboxylic acid derivatives as potent xanthine oxidoreductase inhibitors.
Topics: Animals; Carboxylic Acids; Dose-Response Relationship, Drug; Enzyme Inhibitors; Hyperuricemia; Mice; | 2017 |
Effect and mechanism of dioscin from Dioscorea spongiosa on uric acid excretion in animal model of hyperuricemia.
Topics: Adenine; Animals; Biomarkers; Creatinine; Dioscorea; Diosgenin; Disease Models, Animal; Dose-Respons | 2018 |
Hypouricemic and Nephroprotective Effects of an Active Fraction from Polyrhachis Vicina Roger On Potassium Oxonate-Induced Hyperuricemia in Rats.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Ants; Hyperuricemia; Kidney; Liver; Male; Oxonic Ac | 2018 |
RIP3-deficience attenuates potassium oxonate-induced hyperuricemia and kidney injury.
Topics: Acute Kidney Injury; Animals; Cell Line; Cell Survival; Dose-Response Relationship, Drug; Humans; Hy | 2018 |
Feeding-produced subchronic high plasma levels of uric acid improve behavioral dysfunction in 6-hydroxydopamine-induced mouse model of Parkinson's disease.
Topics: Adrenergic Agents; Animals; Apomorphine; Disease Models, Animal; Hyperuricemia; Male; Mental Disorde | 2019 |
Mangiferin alleviates hypertension induced by hyperuricemia via increasing nitric oxide releases.
Topics: Administration, Oral; Animals; Aorta; C-Reactive Protein; Human Umbilical Vein Endothelial Cells; Hu | 2018 |
Probiotic supplements prevented oxonic acid-induced hyperuricemia and renal damage.
Topics: Animals; Cytoprotection; Dietary Supplements; Dose-Response Relationship, Drug; Hyperuricemia; Kidne | 2018 |
In vivo anti-hyperuricemic and xanthine oxidase inhibitory properties of tuna protein hydrolysates and its isolated fractions.
Topics: Animals; Binding Sites; Chromatography, High Pressure Liquid; Enzyme Inhibitors; Ethanol; Hydrogen B | 2019 |
Anti-hyperuricemic and nephroprotective effects of extracts from Chaenomeles sinensis (Thouin) Koehne in hyperuricemic mice.
Topics: Animals; Creatinine; Disease Models, Animal; Fruit; Gene Expression Regulation; Hyperuricemia; Liver | 2018 |
Anti-Hyperuricemic Effect of 2-Hydroxy-4-methoxy-benzophenone-5-sulfonic Acid in Hyperuricemic Mice through XOD.
Topics: Animals; Benzophenones; Body Weight; Gene Expression Regulation; Glucose Transport Proteins, Facilit | 2018 |
Effect of high uric acid on the disposition of metformin: in vivo and in vitro studies.
Topics: Animals; Antiporters; Cell Line; Humans; Hyperuricemia; Hypoglycemic Agents; Kidney; Liver; Male; Me | 2019 |
A zebrafish (danio rerio) model for high-throughput screening food and drugs with uric acid-lowering activity.
Topics: Allopurinol; Animals; Anserine; Disease Models, Animal; Drug Evaluation, Preclinical; High-Throughpu | 2019 |
New Rice-Derived Short Peptide Potently Alleviated Hyperuricemia Induced by Potassium Oxonate in Rats.
Topics: Animals; Humans; Hyperuricemia; Liver; Male; Oryza; Oxonic Acid; Peptides; Plant Extracts; Rats; Rat | 2019 |
Effects of ChondroT on potassium Oxonate-induced Hyperuricemic mice: downregulation of xanthine oxidase and urate transporter 1.
Topics: Animals; Creatinine; Down-Regulation; Drug Evaluation, Preclinical; Drugs, Chinese Herbal; Humans; H | 2019 |
Modified Chuanhu anti-gout mixture, a traditional Chinese medicine, protects against potassium oxonate-induced hyperuricemia and renal dysfunction in mice.
Topics: Animals; Creatinine; Drugs, Chinese Herbal; Hyperuricemia; Kidney; Male; Mice; Organic Anion Transpo | 2019 |
Changes of drug pharmacokinetics mediated by downregulation of kidney organic cation transporters Mate1 and Oct2 in a rat model of hyperuricemia.
Topics: Adenine; Animals; Antiporters; Cephalexin; Creatinine; Disease Models, Animal; Down-Regulation; Huma | 2019 |
Protective effects of Rhizoma smilacis glabrae extracts on potassium oxonate- and monosodium urate-induced hyperuricemia and gout in mice.
Topics: Animals; Antioxidants; Arthritis, Gouty; Disease Models, Animal; Drugs, Chinese Herbal; Edema; Flavo | 2019 |
Lipidomics coupled with pathway analysis characterizes serum metabolic changes in response to potassium oxonate induced hyperuricemic rats.
Topics: Animals; Biomarkers; Chromatography, High Pressure Liquid; Discriminant Analysis; Hyperuricemia; Lea | 2019 |
Termipaniculatones A-F, chalcone-flavonone heterodimers from Terminthia paniculata, and their protective effects on hyperuricemia and acute gouty arthritis.
Topics: Anacardiaceae; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Gouty; Chalcone; Dose-Re | 2019 |
Anti-hyperuricemic effect of Alpinia oxyphylla seed extract by enhancing uric acid excretion in the kidney.
Topics: Alpinia; Animals; China; Gout; Humans; Hyperuricemia; Kidney; Male; Organic Anion Transport Protein | 2019 |
Preventive Effects of Fucoidan and Fucoxanthin on Hyperuricemic Rats Induced by Potassium Oxonate.
Topics: Animals; Gene Expression Regulation; Hyperuricemia; Kidney; Liver; Oxonic Acid; Polysaccharides; Ran | 2019 |
Curcumin attenuates potassium oxonate-induced hyperuricemia and kidney inflammation in mice.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Biomarkers; Curcumin; Cytokines; Dis | 2019 |
MiR-143-3p directly targets GLUT9 to reduce uric acid reabsorption and inflammatory response of renal tubular epithelial cells.
Topics: Animals; Base Sequence; Case-Control Studies; Chemokine CCL2; Disease Models, Animal; Gene Expressio | 2019 |
Hyperuricemia influences tryptophan metabolism via inhibition of multidrug resistance protein 4 (MRP4) and breast cancer resistance protein (BCRP).
Topics: Acute-Phase Proteins; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette | 2013 |
Fructus Gardenia Extract ameliorates oxonate-induced hyperuricemia with renal dysfunction in mice by regulating organic ion transporters and mOIT3.
Topics: Animals; Blood Urea Nitrogen; Gardenia; Gene Expression Regulation; Humans; Hyperuricemia; Mice; Oxo | 2013 |
Beneficial effect of rutin on oxonate-induced hyperuricemia and renal dysfunction in mice.
Topics: Animals; Carrier Proteins; Glucose Transport Proteins, Facilitative; Hyperuricemia; Kidney Diseases; | 2013 |
Smilax riparia reduces hyperuricemia in mice as a potential treatment of gout.
Topics: Animals; Disease Models, Animal; Down-Regulation; Drugs, Chinese Herbal; Gout; Gout Suppressants; Hy | 2014 |
[Effect of jianpihuashi decoction on rats with hyperuricemia].
Topics: Allopurinol; Animals; Blood Urea Nitrogen; Creatinine; Disease Models, Animal; Drug Combinations; Dr | 2013 |
Effect of commercial or depurinized milk on rat liver growth-regulatory kinases, nuclear factor-kappa B, and endonuclease in experimental hyperuricemia: comparison with allopurinol therapy.
Topics: Allopurinol; Animal Feed; Animals; Diet; Endonucleases; Enzyme Activation; Enzyme Inhibitors; Hyperu | 2014 |
Anti-hyperuricemic and nephroprotective effects of Rhizoma Dioscoreae septemlobae extracts and its main component dioscin via regulation of mOAT1, mURAT1 and mOCT2 in hypertensive mice.
Topics: Animals; Creatinine; Dioscorea; Diosgenin; Dose-Response Relationship, Drug; Drugs, Chinese Herbal; | 2014 |
In vitro and in vivo studies on adlay-derived seed extracts: phenolic profiles, antioxidant activities, serum uric acid suppression, and xanthine oxidase inhibitory effects.
Topics: Animals; Antioxidants; Chlorogenic Acid; Coix; Coumaric Acids; Enzyme Inhibitors; Free Radical Scave | 2014 |
Hypouricemic actions of exopolysaccharide produced by Cordyceps militaris in potassium oxonate-induced hyperuricemic mice.
Topics: Animals; Antimetabolites; Cordyceps; Disease Models, Animal; Hyperuricemia; Liver; Mice; Oxonic Acid | 2014 |
Effects of Smilaxchinoside A and Smilaxchinoside C, two steroidal glycosides from Smilax riparia, on hyperuricemia in a mouse model.
Topics: Animals; Disease Models, Animal; Drugs, Chinese Herbal; Glucose Transport Proteins, Facilitative; Gl | 2014 |
Pallidifloside D, a saponin glycoside constituent from Smilax riparia, resist to hyperuricemia based on URAT1 and GLUT9 in hyperuricemic mice.
Topics: Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Down-Regulation; Glucose Transpor | 2014 |
Nuciferine restores potassium oxonate-induced hyperuricemia and kidney inflammation in mice.
Topics: Animals; Aporphines; Carrier Proteins; Cell Line; Humans; Hyperuricemia; Inflammasomes; Inflammation | 2015 |
Effects of extracts of leaves from Sparattosperma leucanthum on hyperuricemia and gouty arthritis.
Topics: Animals; Anti-Inflammatory Agents; Arthritis, Gouty; Bignoniaceae; Gout Suppressants; Hyperuricemia; | 2015 |
The molecular insight into the antihyperuricemic and renoprotective effect of Shuang Qi gout capsule in mice.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; | 2015 |
Effects of oxonic acid-induced hyperuricemia on mesenteric artery tone and cardiac load in experimental renal insufficiency.
Topics: Analysis of Variance; Animals; Cardiac Output; Disease Models, Animal; Hyperuricemia; Male; Mesenter | 2015 |
[Regulatory effect of leonurus extracts on hyperuricemia in rats].
Topics: Allopurinol; Animals; Blood Urea Nitrogen; Creatinine; Disease Models, Animal; Down-Regulation; Gene | 2014 |
Renal oxidative stress induced by long-term hyperuricemia alters mitochondrial function and maintains systemic hypertension.
Topics: Adenosine Triphosphate; Allopurinol; Animals; Antioxidants; Blood Pressure; Cyclic N-Oxides; Disease | 2015 |
Pallidifloside D from Smilax riparia enhanced allopurinol effects in hyperuricemia mice.
Topics: Allopurinol; Animals; Creatinine; Disease Models, Animal; Drug Synergism; Glucose Transport Proteins | 2015 |
Mangiferin Inhibits Renal Urate Reabsorption by Modulating Urate Transporters in Experimental Hyperuricemia.
Topics: Animals; Anion Transport Proteins; Carrier Proteins; Cytoskeletal Proteins; Hyperuricemia; Kidney; M | 2015 |
Green tea polyphenols decreases uric acid level through xanthine oxidase and renal urate transporters in hyperuricemic mice.
Topics: Animals; Gout Suppressants; Hyperuricemia; Kidney; Liver; Male; Mice; Organic Anion Transport Protei | 2015 |
[The Xanthine Oxidase Inhibitory Activity and Hypouricemic Effects of Crude Drugs Obtained from the Silkworm in Mice].
Topics: Administration, Oral; Animals; Biological Products; Biomarkers; Blood Pressure; Bombyx; Chromatograp | 2015 |
Chinese Herbal Formulas Si-Wu-Tang and Er-Miao-San Synergistically Ameliorated Hyperuricemia and Renal Impairment in Rats Induced by Adenine and Potassium Oxonate.
Topics: Adenine; Administration, Oral; Animals; Benzbromarone; Creatinine; Drug Synergism; Drugs, Chinese He | 2015 |
Hypouricemic and Nephroprotective Effects of Emodinol in Oxonate-Induced Hyperuricemic Mice are Mediated by Organic Ion Transporters and OIT3.
Topics: Animals; Elaeagnaceae; Hyperuricemia; Ion Transport; Kidney; Male; Membrane Proteins; Mice; Molecula | 2016 |
Antioxidative phytochemicals from Rhododendron oldhamii Maxim. leaf extracts reduce serum uric acid levels in potassium oxonate-induced hyperuricemic mice.
Topics: Animals; Antioxidants; Disease Models, Animal; Gout Suppressants; Hyperuricemia; Kidney; Male; Mice; | 2015 |
Melamine Nephrotoxicity is Mediated by Hyperuricemia.
Topics: Animals; Disease Models, Animal; Hyperuricemia; Kidney Diseases; Lipid Peroxidation; Male; Oxonic Ac | 2015 |
Antihyperuricemic effects of thiadiazolopyrimidin-5-one analogues in oxonate treated rats.
Topics: Animals; Catalytic Domain; Creatinine; Enzyme Inhibitors; Hyperuricemia; Kidney; Liver; Male; Molecu | 2016 |
Hypouricaemic action of mangiferin results from metabolite norathyriol via inhibiting xanthine oxidase activity.
Topics: Administration, Oral; Animals; Biomarkers; Biotransformation; Disease Models, Animal; Dose-Response | 2016 |
Difference in the action mechanism of radon inhalation and radon hot spring water drinking in suppression of hyperuricemia in mice.
Topics: Administration, Inhalation; Animals; Antioxidants; Drinking Water; Hot Springs; Hyperuricemia; Kidne | 2016 |
Effect of Soy Sauce on Serum Uric Acid Levels in Hyperuricemic Rats and Identification of Flazin as a Potent Xanthine Oxidase Inhibitor.
Topics: Animals; Body Weight; Carbolines; Drug Evaluation, Preclinical; Enzyme Inhibitors; Furans; Hyperuric | 2016 |
Astilbin improves potassium oxonate-induced hyperuricemia and kidney injury through regulating oxidative stress and inflammation response in mice.
Topics: Animals; Carrier Proteins; Flavonols; Hyperuricemia; Inflammasomes; Inflammation; Janus Kinase 2; Ki | 2016 |
Effects of extracts from Corylopsis coreana Uyeki (Hamamelidaceae) flos on xanthine oxidase activity and hyperuricemia.
Topics: Animals; Biomarkers; Disease Models, Animal; Dose-Response Relationship, Drug; Enzyme Inhibitors; Et | 2016 |
Hypouricemic effects of Mesona procumbens Hemsl. through modulating xanthine oxidase activity in vitro and in vivo.
Topics: Animals; Humans; Hyperuricemia; Lamiaceae; Liver; Mice; Mice, Inbred ICR; Oxonic Acid; Plant Extract | 2016 |
Actions of water extract from Cordyceps militaris in hyperuricemic mice induced by potassium oxonate combined with hypoxanthine.
Topics: Animals; Blood Urea Nitrogen; Cordyceps; Creatinine; Dose-Response Relationship, Drug; Hyperuricemia | 2016 |
Antihyperuricemic effect of liquiritigenin in potassium oxonate-induced hyperuricemic rats.
Topics: Animals; Dose-Response Relationship, Drug; Female; Flavanones; Gout Suppressants; Hyperuricemia; Mal | 2016 |
Potassium oxonate induces acute hyperuricemia in the tree shrew (tupaia belangeri chinensis).
Topics: Acute Disease; Allopurinol; Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Enzym | 2017 |
Oxonic acid-induced hyperuricemia elevates plasma aldosterone in experimental renal insufficiency.
Topics: Aldosterone; Animal Feed; Animals; Autoradiography; Blood Pressure; Disease Models, Animal; Hyperten | 2008 |
Essential oil from leaves of Cinnamomum osmophloeum acts as a xanthine oxidase inhibitor and reduces the serum uric acid levels in oxonate-induced mice.
Topics: Acrolein; Administration, Oral; Allopurinol; Animals; Cinnamomum; Enzyme Inhibitors; Gout Suppressan | 2008 |
Lithospermic acid as a novel xanthine oxidase inhibitor has anti-inflammatory and hypouricemic effects in rats.
Topics: Allopurinol; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Gouty; Benzofurans; Depsid | 2008 |
Role of oxidative stress in the renal abnormalities induced by experimental hyperuricemia.
Topics: Aldehydes; Angiotensin II; Animals; Antioxidants; Arterioles; Body Weight; Cyclic N-Oxides; Disease | 2008 |
Activation of ATP-sensitive potassium channels protects vascular endothelial cells from hypertension and renal injury induced by hyperuricemia.
Topics: 6-Ketoprostaglandin F1 alpha; Angiotensin II; Angiotensins; Animals; Cells, Cultured; Disease Models | 2008 |
Hyperuricemia, oxidative stress, and carotid artery tone in experimental renal insufficiency.
Topics: Animals; Carotid Arteries; Creatinine; Dinoprost; Hyperuricemia; Male; Nephrectomy; NG-Nitroarginine | 2009 |
Relative efficacy of casein or soya protein combined with palm or safflower-seed oil on hyperuricaemia in rats.
Topics: Albumins; Analysis of Variance; Animals; Blood Urea Nitrogen; Caseins; Cholesterol; Creatinine; Diet | 2010 |
Simiao pill ameliorates urate underexcretion and renal dysfunction in hyperuricemic mice.
Topics: Allopurinol; Animals; Biological Transport; Gout; Hyperuricemia; Kidney; Male; Mice; Mice, Inbred St | 2010 |
Phytochemicals from Acacia confusa heartwood extracts reduce serum uric acid levels in oxonate-induced mice: their potential use as xanthine oxidase inhibitors.
Topics: Acacia; Animals; Drug Discovery; Enzyme Inhibitors; Flavonoids; Hyperuricemia; Male; Mice; Mice, Inb | 2010 |
Hyperuricemia attenuates aortic nitric oxide generation, through inhibition of arginine transport, in rats.
Topics: Allopurinol; Animals; Aorta; Arginine; Benzbromarone; Biological Transport; Blood Pressure; Cationic | 2011 |
[Mangiferin promotes uric acid excretion and kidney function improvement and modulates related renal transporters in hyperuricemic mice].
Topics: Animals; Blood Urea Nitrogen; Carrier Proteins; Creatinine; Glucose Transport Proteins, Facilitative | 2010 |
Hypouricemic effects of anthocyanin extracts of purple sweet potato on potassium oxonate-induced hyperuricemia in mice.
Topics: Allopurinol; Animals; Anthocyanins; Disease Models, Animal; Hyperuricemia; Ipomoea batatas; Male; Mi | 2011 |
Protective effects of cortex fraxini coumarines against oxonate-induced hyperuricemia and renal dysfunction in mice.
Topics: Aesculus; Animals; Coumarins; Drugs, Chinese Herbal; Gene Expression Regulation; Hyperuricemia; Kidn | 2011 |
Identification of novel isocytosine derivatives as xanthine oxidase inhibitors from a set of virtual screening hits.
Topics: Animals; Computer Simulation; Cytosine; Enzyme Activation; Enzyme Inhibitors; Hyperuricemia; Male; O | 2012 |
Anti-hyperuricemic and nephroprotective effects of Modified Simiao Decoction in hyperuricemic mice.
Topics: Animals; Drugs, Chinese Herbal; Hyperuricemia; Kidney; Liver; Male; Malondialdehyde; Mice; Mice, Inb | 2012 |
Pharmacological basis for use of Lychnophora trichocarpha in gouty arthritis: anti-hyperuricemic and anti-inflammatory effects of its extract, fraction and constituents.
Topics: Acetates; Animals; Anti-Inflammatory Agents; Arthritis, Gouty; Asteraceae; Ethanol; Flavonoids; Hype | 2012 |
Hypouricemic effect of the methanol extract from Prunus mume fruit in mice.
Topics: Administration, Oral; Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Fruit; Hype | 2012 |
Antihyperuricemic and nephroprotective effects of resveratrol and its analogues in hyperuricemic mice.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; | 2012 |
Reducing effect of mangiferin on serum uric acid levels in mice.
Topics: Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Gout; | 2012 |
Longan seed extract reduces hyperuricemia via modulating urate transporters and suppressing xanthine oxidase activity.
Topics: Allopurinol; Animals; Glucose Transporter Type 1; Gout; Gout Suppressants; Hyperuricemia; Hypoxanthi | 2012 |
The antinociceptive and anti-inflammatory effects of the crude extract of Jatropha isabellei in a rat gout model.
Topics: Alkaloids; Animals; Anti-Inflammatory Agents; Arthritis, Gouty; Biomarkers, Pharmacological; Disease | 2013 |
Synergistic effect of uricase blockade plus physiological amounts of fructose-glucose on glomerular hypertension and oxidative stress in rats.
Topics: Animals; Beverages; Fatty Liver; Fructokinases; Fructose; Glucose; Hypertrophy; Hyperuricemia; Insul | 2013 |
Administration of procyanidins from grape seeds reduces serum uric acid levels and decreases hepatic xanthine dehydrogenase/oxidase activities in oxonate-treated mice.
Topics: Allopurinol; Animals; Antioxidants; Biflavonoids; Catechin; Disease Models, Animal; Dose-Response Re | 2004 |
[Xanthine oxidase inhibitory activity and hypouricemia effect of propolis in rats].
Topics: Animals; Anti-Infective Agents; Brazil; Caffeic Acids; China; Coumaric Acids; Disease Models, Animal | 2005 |
The dual actions of morin (3,5,7,2',4'-pentahydroxyflavone) as a hypouricemic agent: uricosuric effect and xanthine oxidase inhibitory activity.
Topics: Alkaline Phosphatase; Animals; Antioxidants; Creatinine; Enzyme Inhibitors; Flavonoids; Hyperuricemi | 2006 |
Effects of cassia oil on serum and hepatic uric acid levels in oxonate-induced mice and xanthine dehydrogenase and xanthine oxidase activities in mouse liver.
Topics: Administration, Oral; Allopurinol; Animals; Cinnamomum aromaticum; Dose-Response Relationship, Drug; | 2006 |
Hypouricemic effects of acacetin and 4,5-o-dicaffeoylquinic acid methyl ester on serum uric acid levels in potassium oxonate-pretreated rats.
Topics: Administration, Oral; Allopurinol; Animals; Chrysanthemum; Disease Models, Animal; Dose-Response Rel | 2005 |
Effect and mechanism of total saponin of Dioscorea on animal experimental hyperuricemia.
Topics: Animals; Dioscorea; Disease Models, Animal; Hyperuricemia; Injections, Intraperitoneal; Liver; Male; | 2006 |
Xanthine oxidase inhibitory activity of some Indian medical plants.
Topics: Animals; Female; Hyperuricemia; India; Lethal Dose 50; Magnoliopsida; Male; Medicine, Traditional; M | 2007 |
Effects of acute and chronic L-arginine treatment in experimental hyperuricemia.
Topics: Animals; Arginine; Arterioles; Endothelium, Vascular; Hypertension; Hyperuricemia; Kidney Glomerulus | 2007 |
Uric acid heralds ischemic tissue injury to mobilize endothelial progenitor cells.
Topics: Adenosine; Animals; Cell Movement; Chronic Disease; Endothelial Cells; Hyperuricemia; Inosine; Ische | 2007 |
Hypouricemic action of selected flavonoids in mice: structure-activity relationships.
Topics: Animals; Flavonoids; Hyperuricemia; Liver; Male; Mice; Mice, Inbred ICR; Oxonic Acid; Structure-Acti | 2007 |
Treatment with the xanthine oxidase inhibitor febuxostat lowers uric acid and alleviates systemic and glomerular hypertension in experimental hyperuricaemia.
Topics: Animals; Blood Pressure; Febuxostat; Follow-Up Studies; Gout Suppressants; Hypertension, Renal; Hype | 2008 |
Flavonoids of Cynara scolymus possess potent xanthinoxidase inhibitory activity in vitro but are devoid of hypouricemic effects in rats after oral application.
Topics: Administration, Oral; Animals; Cynara scolymus; Flavonoids; Gout; Hyperuricemia; Male; Oxonic Acid; | 2008 |
Hypouricemic effects of phenylpropanoid glycosides acteoside of Scrophularia ningpoensis on serum uric acid levels in potassium oxonate-pretreated Mice.
Topics: Animals; Glycosides; Hyperuricemia; Male; Mice; Mice, Inbred ICR; Oxonic Acid; Plant Extracts; Plant | 2008 |
Effect of febuxostat on the progression of renal disease in 5/6 nephrectomy rats with and without hyperuricemia.
Topics: Animals; Disease Models, Animal; Febuxostat; Hyperuricemia; Kidney; Kidney Failure, Chronic; Male; M | 2008 |